Eli Lilly and (LLY) 10-K 22 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 17, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-06351
Entity Registrant Name	ELI LILLY AND COMPANY
Entity Incorporation, State or Country Code	IN
Entity Tax Identification Number	35-0470950
Entity Address, Address Line One	Lilly Corporate Center
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46285
City Area Code	317
Local Phone Number	276-2000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 274,342
Entity Common Stock, Shares Outstanding		950,296,118
Documents Incorporated by Reference	Portions of the Registrant's Proxy Statement for the 2023 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.
Document Annual Report	true
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0000059478
Common Stock (no par value)
Document Information [Line Items]
Title of 12(b) Security	Common Stock (no par value)
Trading Symbol	LLY
Security Exchange Name	NYSE
7 1/8% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	7 1/8% Notes due 2025
Trading Symbol	LLY25
Security Exchange Name	NYSE
1.625% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	1.625% Notes due 2026
Trading Symbol	LLY26
Security Exchange Name	NYSE
2.125% Notes due 2030
Document Information [Line Items]
Title of 12(b) Security	2.125% Notes due 2030
Trading Symbol	LLY30
Security Exchange Name	NYSE
0.625% Notes due 2031
Document Information [Line Items]
Title of 12(b) Security	0.625% Notes due 2031
Trading Symbol	LLY31
Security Exchange Name	NYSE
0.500% Notes due 2033
Document Information [Line Items]
Title of 12(b) Security	0.500% Notes due 2033
Trading Symbol	LLY33
Security Exchange Name	NYSE
6.77% Notes due 2036
Document Information [Line Items]
Title of 12(b) Security	6.77% Notes due 2036
Trading Symbol	LLY36
Security Exchange Name	NYSE
1.625% Notes due 2043
Document Information [Line Items]
Title of 12(b) Security	1.625% Notes due 2043
Trading Symbol	LLY43
Security Exchange Name	NYSE
1.700% Notes due 2049
Document Information [Line Items]
Title of 12(b) Security	1.700% Notes due 2049
Trading Symbol	LLY49A
Security Exchange Name	NYSE
1.125% Notes due 2051
Document Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2051
Trading Symbol	LLY51
Security Exchange Name	NYSE
1.375% Notes due 2061
Document Information [Line Items]
Title of 12(b) Security	1.375% Notes due 2061
Trading Symbol	LLY61
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Indianapolis, Indiana

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue (Note 2)	$ 28,541.4	$ 28,318.4	$ 24,539.8
Costs, expenses, and other:
Cost of sales	6,629.8	7,312.8	5,483.3
Research and development	7,190.8	6,930.7	5,976.3
Marketing, selling, and administrative	6,440.4	6,431.6	6,121.2
Acquired in-process research and development and development milestones (Note 3)	908.5	970.1	769.8
Asset impairment, restructuring, and other special charges (Note 5)	244.6	316.1	131.2
Other—net, (income) expense (Note 18)	320.9	201.6	(1,171.9)
Costs, expenses, and other	21,735	22,162.9	17,309.9
Income before income taxes	6,806.4	6,155.5	7,229.9
Income taxes (Note 14)	561.6	573.8	1,036.2
Net income	$ 6,244.8	$ 5,581.7	$ 6,193.7
Earnings per share:
Basic (in dollars per share)	$ 6.93	$ 6.15	$ 6.82
Diluted (in dollars per share)	$ 6.90	$ 6.12	$ 6.79
Shares used in calculation of earnings per share:
Basic (in shares)	901,736	906,963	907,634
Diluted (in shares)	904,619	911,681	912,505

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 6,244.8	$ 5,581.7	$ 6,193.7
Other comprehensive income (loss):
Change in foreign currency translation gains (losses)	(248.1)	13.5	122.1
Change in net unrealized gains (losses) on securities	(53.2)	(15.9)	14.2
Change in defined benefit pension and retiree health benefit plans (Note 15)	616.9	2,699.4	(157.1)
Change in effective portion of cash flow hedges	432.9	151.6	(152.9)
Other comprehensive income (loss) before income taxes	748.5	2,848.6	(173.7)
Benefit (provision) for income taxes related to other comprehensive income (loss)	(250)	(695.3)	200.9
Other comprehensive income, net of tax (Note 17)	498.5	2,153.3	27.2
Comprehensive income	$ 6,743.3	$ 7,735	$ 6,220.9

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents (Note 7)	$ 2,067	$ 3,818.5
Short-term investments (Note 7)	144.8	90.1
Accounts receivable, net of allowances of $16.0 (2022) and $22.5 (2021)	6,896	6,672.8
Other receivables	1,662.9	1,454.4
Inventories (Note 6)	4,309.7	3,886
Prepaid expenses and other current assets	2,954.1	2,530.6
Total current assets	18,034.5	18,452.4
Investments (Note 7)	2,901.8	3,212.6
Goodwill (Note 8)	4,073	3,892
Other intangibles, net (Note 8)	7,206.6	7,691.9
Deferred tax assets (Note 14)	2,792.9	2,489.3
Property and equipment, net (Note 9)	10,144	8,985.1
Other noncurrent assets	4,337	4,082.7
Total assets	49,489.8	48,806
Current Liabilities
Short-term borrowings and current maturities of long-term debt (Note 11)	1,501.1	1,538.3
Accounts payable	1,930.6	1,670.6
Employee compensation	1,059.8	958.1
Sales rebates and discounts	8,784.1	6,845.8
Dividends payable	1,017.2	885.5
Income taxes payable (Note 14)	475.1	126.9
Other current liabilities	2,370.3	3,027.5
Total current liabilities	17,138.2	15,052.7
Other Liabilities
Long-term debt (Note 11)	14,737.5	15,346.4
Accrued retirement benefits (Note 15)	1,305.1	1,954.1
Long-term income taxes payable (Note 14)	3,709.6	3,920
Deferred tax liabilities (Note 14)	87.3	1,733.7
Other noncurrent liabilities	1,736.7	1,644.3
Total other liabilities	21,576.2	24,598.5
Commitments and Contingencies (Note 16)
Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022) and 954,116 (2021)	594.1	596.3
Additional paid-in capital	6,921.4	6,833.4
Retained earnings	10,042.6	8,958.5
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 17)	(3,844.6)	(4,343.1)
Cost of common stock in treasury	(50.5)	(52.7)
Total Eli Lilly and Company shareholders' equity	10,649.8	8,979.2
Noncontrolling interests	125.6	175.6
Total equity	10,775.4	9,154.8
Total liabilities and equity	$ 49,489.8	$ 48,806

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 16	$ 22.5
Common stock, shares authorized (in shares)	3,200,000,000	3,200,000,000
Common stock, shares, issued (in shares)	950,632,000	954,116,000

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Employee Benefit Trust	Accumulated Other Comprehensive Loss	Common Stock in Treasury	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2019		958,056
Beginning balance (in shares) at Dec. 31, 2019							530
Beginning balance at Dec. 31, 2019		$ 598.8	$ 6,685.3	$ 4,920.4	$ (3,013.2)	$ (6,523.6)	$ (60.8)	$ 92.2
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				6,193.7				126.6
Other comprehensive income, net of tax	$ 27.2					27.2
Cash dividends declared				(2,786.2)
Retirement of treasury shares (in shares)		(3,627)					(3,627)
Retirement of treasury shares		$ (2.3)		(497.7)			$ 500
Purchase of treasury shares (in shares)							3,627
Purchase of treasury shares	(500)						$ (500)
Issuance of stock under employee stock plans, net (in shares)		2,648					(43)
Issuance of stock under employee stock plans, net		$ 1.7	(212.7)				$ 5.1
Stock-based compensation			308.1
Other			(2.2)					(35.2)
Ending balance (in shares) at Dec. 31, 2020		957,077
Ending balance (in shares) at Dec. 31, 2020							487
Ending balance at Dec. 31, 2020		$ 598.2	6,778.5	7,830.2	(3,013.2)	(6,496.4)	$ (55.7)	183.6
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				5,581.7				3.4
Other comprehensive income, net of tax	2,153.3					2,153.3
Cash dividends declared				(3,201.7)
Retirement of treasury shares (in shares)		(5,412)					(5,412)
Retirement of treasury shares		$ (3.4)		(1,246.6)			$ 1,250
Purchase of treasury shares (in shares)							5,412
Purchase of treasury shares	$ (1,250)						$ (1,250)
Issuance of stock under employee stock plans, net (in shares)		2,451					(24)
Issuance of stock under employee stock plans, net		$ 1.5	(287.9)				$ 3
Stock-based compensation			342.8
Other				(5.1)				(11.4)
Ending balance (in shares) at Dec. 31, 2021	954,116	954,116
Ending balance (in shares) at Dec. 31, 2021							463
Ending balance at Dec. 31, 2021	$ 9,154.8	$ 596.3	6,833.4	8,958.5	(3,013.2)	(4,343.1)	$ (52.7)	175.6
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				6,244.8				(20.9)
Other comprehensive income, net of tax	498.5					498.5
Cash dividends declared				(3,667.5)
Retirement of treasury shares (in shares)		(5,607)					(5,607)
Retirement of treasury shares		$ (3.5)		(1,496.5)			$ 1,500
Purchase of treasury shares (in shares)							5,607
Purchase of treasury shares	$ (1,500)						$ (1,500)
Issuance of stock under employee stock plans, net (in shares)		2,123					(13)
Issuance of stock under employee stock plans, net		$ 1.3	(283.1)				$ 2.2
Stock-based compensation			371.1
Other				3.3				(29.1)
Ending balance (in shares) at Dec. 31, 2022	950,632	950,632
Ending balance (in shares) at Dec. 31, 2022							450
Ending balance at Dec. 31, 2022	$ 10,775.4	$ 594.1	$ 6,921.4	$ 10,042.6	$ (3,013.2)	$ (3,844.6)	$ (50.5)	$ 125.6

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Cash dividend declared per share (in usd per share)	$ 4.07	$ 3.53	$ 3.07

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities
Net income	$ 6,244.8	$ 5,581.7	$ 6,193.7
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,522.5	1,547.6	1,323.9
Debt extinguishment loss (Note 11)	0	405.2	0
Change in deferred income taxes	(2,185.2)	(802.3)	(134.5)
Stock-based compensation expense	371.1	342.8	308.1
Net investment (gains) losses	420	(178)	(1,438.5)
Acquired in-process research and development and development milestones (Note 3)	420.9	874.9	660.4
Other non-cash operating activities, net	304.8	511.4	333.9
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables—(increase) decrease	(299.6)	(1,278.3)	(1,350.2)
Inventories—(increase) decrease	(599.7)	(235.9)	(533.4)
Other assets—(increase) decrease	(793.5)	1,515.4	(457.1)
Income taxes payable—increase (decrease)	346.6	(359.7)	322
Accounts payable and other liabilities—increase (decrease)	1,331.7	(664.1)	1,271.3
Net Cash Provided by Operating Activities	7,084.4	7,260.7	6,499.6
Cash Flows from Investing Activities
Purchases of property and equipment	(1,854.3)	(1,309.8)	(1,387.9)
Proceeds from sales and maturities of short-term investments	121.4	47.4	129.7
Purchases of short-term investments	(107.4)	(83.5)	(11.4)
Proceeds from sales of noncurrent investments	342.2	800	757.1
Purchases of noncurrent investments	(600.2)	(929.9)	(358.7)
Purchases of in-process research and development	(629.7)	(563.4)	(641.2)
Cash paid for acquisitions, net of cash acquired (Note 3)	(327.2)	(747.4)	(849.3)
Other investing activities, net	(206.4)	24.3	102.8
Net Cash Used for Investing Activities	(3,261.6)	(2,762.3)	(2,258.9)
Cash Flows from Financing Activities
Dividends paid	(3,535.8)	(3,086.8)	(2,687.1)
Net change in short-term borrowings	1,498	(4)	(1,494.2)
Proceeds from issuance of long-term debt	0	2,410.8	2,062.3
Repayments of long-term debt	(1,560)	(1,905.4)	(276.5)
Purchases of common stock	(1,500)	(1,250)	(500)
Other financing activities, net	(308.9)	(295.9)	(241.6)
Net Cash Used for Financing Activities	(5,406.7)	(4,131.3)	(3,137.1)
Effect of exchange rate changes on cash and cash equivalents	(167.6)	(205.7)	216
Net increase (decrease) in cash and cash equivalents	(1,751.5)	161.4	1,319.6
Cash and cash equivalents at beginning of year	3,818.5	3,657.1	2,337.5
Cash and Cash Equivalents at End of Year	$ 2,067	$ 3,818.5	$ 3,657.1

Summary of Significant Accounti

Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards	Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards Basis of Presentation The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K. Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation. We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Research and Development Expenses and Acquired In-Process Research and Development (IPR&D) and Development Milestones Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations. Acquired IPR&D and development milestones include the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. Earnings Per Share (EPS) All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs. Foreign Currency Translation Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss). Advertising Expenses Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and internet advertising, totaled approximately $1.0 billion, $1.2 billion, and $1.1 billion in 2022, 2021, and 2020, respectively, which was less than 5 percent of revenue each year. Other Significant Accounting Policies Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements. Implementation of New Financial Accounting Standards Accounting Standards Update (ASU) 2021-10, Government Assistance , establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. ASU 2020-04, Reference Rate Reform , as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The following table summarizes our revenue recognized in our consolidated statements of operations: 2022 2021 2020 Net product revenue $ 25,462.8 $ 25,957.9 $ 22,694.8 Collaboration and other revenue (1) 3,078.6 2,360.5 1,845.0 Revenue $ 28,541.4 $ 28,318.4 $ 24,539.8 (1) Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively. We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance ® and Trajenta ® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers. Net Product Revenue Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related product sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer. Most of our products are sold to wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. For the years ended December 31, 2022, 2021, and 2020, our three largest wholesalers each accounted for between 16 percent and 21 percent of consolidated revenue. Further, they each accounted for between 18 percent and 29 percent of accounts receivable as of December 31, 2022 and 2021. Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts, and returns. The following describe the most significant of these judgments: Sales Rebates and Discounts - Background and Uncertainties • We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates. • The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach. • The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods. • Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale. Sales Returns - Background and Uncertainties • When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuations, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return most of our products for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material. • As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns. • Actual U.S. product returns have been less than 2 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. Adjustments to Revenue Adjustments to increase revenue, recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods, were less than 1 percent of U.S. revenue during each of the years ended December 31, 2022, 2021, and 2020. Collaboration and Other Arrangements We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. • Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue. • Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned. • Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue. • For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known. • Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. Contract Liabilities Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. The following table summarizes contract liability balances: 2022 2021 Contract liabilities $ 219.2 $ 262.6 The contract liabilities balances disclosed above as of December 31, 2022 and 2021 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time. During the years ended December 31, 2022, 2021, and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year. Disaggregation of Revenue The following table summarizes revenue by product: U.S. Outside U.S. 2022 2021 2020 2022 2021 2020 Revenue—to unaffiliated customers: Diabetes: Trulicity ® $ 5,688.8 $ 4,914.4 $ 3,835.9 $ 1,750.9 $ 1,557.6 $ 1,232.2 Jardiance (1) 1,194.5 807.3 620.8 871.5 683.5 533.0 Humalog ® (2) 1,191.9 1,320.7 1,485.6 868.7 1,132.3 1,140.3 Humulin ® 730.2 832.9 866.4 289.2 389.6 393.2 Basaglar ® 470.7 588.3 842.3 289.7 304.2 282.1 Mounjaro ® 366.6 — — 115.9 — — Other diabetes 268.4 255.7 258.1 367.8 401.6 344.5 Total diabetes 9,911.1 8,719.3 7,909.1 4,553.7 4,468.8 3,925.3 Oncology: Verzenio ® 1,653.2 834.9 618.2 830.3 515.0 294.4 Cyramza ® 351.4 358.1 381.9 620.0 674.8 650.8 Alimta ® 543.7 1,233.9 1,265.3 384.0 827.5 1,064.7 Erbitux ® 500.1 481.8 480.1 66.4 66.4 56.3 Tyvyt ® — — — 293.3 418.1 308.7 Other oncology 169.7 120.1 46.6 254.1 210.7 152.3 Total oncology 3,218.1 3,028.8 2,792.1 2,448.1 2,712.5 2,527.2 Immunology: Taltz ® 1,724.6 1,542.4 1,288.5 757.4 670.4 500.0 Olumiant ® (3) 148.2 324.1 63.8 682.3 791.0 575.0 Other immunology 20.0 15.3 20.0 12.1 17.6 14.6 Total immunology 1,892.8 1,881.8 1,372.3 1,451.8 1,479.0 1,089.6 Neuroscience: Emgality ® 462.8 434.5 325.9 188.1 142.7 37.0 Zyprexa ® 30.4 39.6 46.1 306.5 390.7 360.5 Cymbalta ® 33.7 38.7 42.1 249.6 542.8 725.6 Other neuroscience 85.5 102.0 73.2 189.6 207.5 220.9 Total neuroscience 612.4 614.8 487.3 933.8 1,283.7 1,344.0 Other: COVID-19 antibodies (4) 2,008.9 1,978.0 850.0 14.7 261.4 21.2 Forteo ® 367.3 441.6 510.3 245.8 360.3 536.0 Cialis ® 35.2 10.6 61.8 552.1 707.9 545.4 Other 144.2 136.1 246.4 151.3 233.9 321.8 Total other 2,555.7 2,566.4 1,668.4 964.0 1,563.5 1,424.4 Revenue $ 18,190.0 $ 16,811.0 $ 14,229.3 $ 10,351.3 $ 11,507.4 $ 10,310.5 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi ® , Synjardy ® , and Trijardy ® XR. (2) Humalog revenue includes insulin lispro. (3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area: 2022 2021 2020 Revenue—to unaffiliated customers (1) : U.S. $ 18,190.0 $ 16,811.0 $ 14,229.3 Europe 4,299.2 4,776.8 4,187.7 Japan 1,747.3 2,367.0 2,583.1 China 1,452.8 1,661.4 1,116.9 Other foreign countries 2,852.0 2,702.2 2,422.7 Revenue $ 28,541.4 $ 28,318.4 $ 24,539.8 Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process. In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition. We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&D and development milestone charges of $908.5 million, $970.1 million, and $769.8 million for the years ended December 31, 2022, 2021, and 2020, respectively. Acquisitions of Businesses Akouos Acquisition Overview of Transaction In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122 million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma. Assets Acquired and Liabilities Assumed Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized. The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at December 1, 2022 Cash $ 153.2 Acquired IPR&D (1) 184.0 Goodwill (2) 181.2 Other assets and liabilities, net 28.9 Acquisition date fair value of consideration transferred 547.3 Less: Cash acquired (153.2) Fair value of CVR liability (3) (66.9) Cash paid, net of cash acquired $ 327.2 (1) Acquired IPR&D intangibles primarily relate to GJB2. (2) The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. (3) See Note 7 for a discussion on the estimation of the CVR liability. The results of operations attributable to Akouos for the year ended December 31, 2022 were immaterial. Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021. Prevail Acquisition Overview of Transaction In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment. Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 22, 2021 Cash $ 90.5 Acquired IPR&D (1) 824.0 Goodwill (2) 126.8 Deferred tax liabilities (106.0) Other assets and liabilities, net (31.5) Acquisition date fair value of consideration transferred 903.8 Less: Cash acquired (90.5) Fair value of CVR liability (3) (65.9) Cash paid, net of cash acquired $ 747.4 (1) Acquired IPR&D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information. (2) The goodwill recognized from this acquisition is not deductible for tax purposes. (3) See Note 7 for a discussion on the estimation of the CVR liability. The results of operations attributable to Prevail for the years ended December 31, 2022 and 2021 were immaterial. Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020. Dermira Acquisition Overview of Transaction In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza ® (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. Assets Acquired and Liabilities Assumed The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira. Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December 31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December 31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020. Asset Acquisitions The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020. Counterparty Compound(s),Therapy, or Asset Acquisition Month Phase of Development (1) Acquired IPR&D Expense BioMarin Pharmaceutical Inc. Priority Review Voucher February 2022 Not applicable $ 110.0 Foghorn Therapeutics Inc. Pre-clinical targets that could lead to potential new oncology medicines December 2021 Pre-clinical 316.6 Rigel Pharmaceuticals, Inc. R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases March 2021 Phase I 125.0 Precision Biosciences, Inc. Potential in vivo therapies for genetic disorders January 2021 Pre-clinical 107.8 Innovent Biologics, Inc. (Innovent) Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China (2) October 2020 Phase III 200.0 Petra Pharma Corporation (Petra) Mutant-selective PI3K α inhibitor that could lead to potential new medicine May 2020 Pre-clinical 174.8 Disarm Therapeutics, Inc. Disease-modifying therapeutics program for patients with axonal degeneration October 2020 Pre-clinical 126.3 (1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. (2) In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent. In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K α
Acquisitions	Acquisitions We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process. In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition. We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&D and development milestone charges of $908.5 million, $970.1 million, and $769.8 million for the years ended December 31, 2022, 2021, and 2020, respectively. Acquisitions of Businesses Akouos Acquisition Overview of Transaction In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122 million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma. Assets Acquired and Liabilities Assumed Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized. The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at December 1, 2022 Cash $ 153.2 Acquired IPR&D (1) 184.0 Goodwill (2) 181.2 Other assets and liabilities, net 28.9 Acquisition date fair value of consideration transferred 547.3 Less: Cash acquired (153.2) Fair value of CVR liability (3) (66.9) Cash paid, net of cash acquired $ 327.2 (1) Acquired IPR&D intangibles primarily relate to GJB2. (2) The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. (3) See Note 7 for a discussion on the estimation of the CVR liability. The results of operations attributable to Akouos for the year ended December 31, 2022 were immaterial. Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021. Prevail Acquisition Overview of Transaction In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment. Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 22, 2021 Cash $ 90.5 Acquired IPR&D (1) 824.0 Goodwill (2) 126.8 Deferred tax liabilities (106.0) Other assets and liabilities, net (31.5) Acquisition date fair value of consideration transferred 903.8 Less: Cash acquired (90.5) Fair value of CVR liability (3) (65.9) Cash paid, net of cash acquired $ 747.4 (1) Acquired IPR&D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information. (2) The goodwill recognized from this acquisition is not deductible for tax purposes. (3) See Note 7 for a discussion on the estimation of the CVR liability. The results of operations attributable to Prevail for the years ended December 31, 2022 and 2021 were immaterial. Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020. Dermira Acquisition Overview of Transaction In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza ® (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. Assets Acquired and Liabilities Assumed The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira. Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December 31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December 31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020. Asset Acquisitions The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020. Counterparty Compound(s),Therapy, or Asset Acquisition Month Phase of Development (1) Acquired IPR&D Expense BioMarin Pharmaceutical Inc. Priority Review Voucher February 2022 Not applicable $ 110.0 Foghorn Therapeutics Inc. Pre-clinical targets that could lead to potential new oncology medicines December 2021 Pre-clinical 316.6 Rigel Pharmaceuticals, Inc. R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases March 2021 Phase I 125.0 Precision Biosciences, Inc. Potential in vivo therapies for genetic disorders January 2021 Pre-clinical 107.8 Innovent Biologics, Inc. (Innovent) Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China (2) October 2020 Phase III 200.0 Petra Pharma Corporation (Petra) Mutant-selective PI3K α inhibitor that could lead to potential new medicine May 2020 Pre-clinical 174.8 Disarm Therapeutics, Inc. Disease-modifying therapeutics program for patients with axonal degeneration October 2020 Pre-clinical 126.3 (1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. (2) In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent. In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K α

Collaborations and Other Arrang

Collaborations and Other Arrangements	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations and Other Arrangements	Collaborations and Other Arrangements We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. Boehringer Ingelheim Diabetes Collaboration We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto ® as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: Net Milestones Capitalized (Deferred) (1) 2022 2021 Jardiance $ 116.2 $ 136.1 Trajenta 63.5 88.5 Basaglar (130.6) (149.3) (1) This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales. The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar: 2022 2021 2020 Jardiance $ 2,066.0 $ 1,490.8 $ 1,153.8 Basaglar 760.4 892.5 1,124.4 Trajenta 383.7 372.5 358.5 Olumiant We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million and $260.0 million were capitalized as intangible assets as of December 31, 2022 and 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period. As of December 31, 2022, Incyte is eligible to receive up to $100.0 million of additional payments from us in potential sales-based milestones. We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant: 2022 2021 2020 Olumiant $ 830.5 $ 1,115.1 $ 638.9 COVID-19 Antibodies We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences received royalty payments in the mid-teens on our net sales of etesevimab. Pursuant to EUAs or similar regulatory authorizations, we recognized $2.02 billion, $2.24 billion, and $871.2 million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December 31, 2022, 2021, and 2020, respectively. Tyvyt We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt: 2022 2021 2020 Tyvyt $ 293.3 $ 418.1 $ 308.7 Lebrikizumab We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December 31, 2022, Roche is eligible to receive up to $165.0 million of additional payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the year ended December 31, 2022, milestone payments to Roche were not material.

Asset Impairment, Restructuring

Asset Impairment, Restructuring, and Other Special Charges	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Asset Impairment, Restructuring, And Other Special Charges	Asset Impairment, Restructuring, and Other Special Charges The components of the charges included in asset impairment, restructuring, and other special charges 2022 2021 2020 Asset impairment (gain) and other special charges $ 221.6 $ 303.1 $ (20.0) Severance 23.0 13.0 151.2 Total asset impairment, restructuring, and other special charges $ 244.6 $ 316.1 $ 131.2 Asset impairment, restructuring, and other special charges recognized during the year ended December 31, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing. During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. Inventories at December 31 consisted of the following: 2022 2021 Finished products $ 901.2 $ 761.9 Work in process 2,597.7 2,372.7 Raw materials and supplies 801.9 717.2 Total (approximates replacement cost) 4,300.8 3,851.8 Increase to LIFO cost 8.9 34.2 Inventories $ 4,309.7 $ 3,886.0 Inventories valued under the LIFO method comprised $1.23 billion and $1.36 billion of total inventories at December 31, 2022 and 2021, respectively.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments Investments in Equity and Debt Securities Our equity investments are accounted for using three different methods depending on the type of equity investment: • Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. • For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. • Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December 31, 2022, 2021, and 2020 were not material. The net gains (losses) recognized in our consolidated statements of operations for equity securities were $(410.7) million, $176.9 million, and $1.44 billion for the years ended December 31, 2022, 2021, and 2020, respectively. The net gains (losses) recognized for the years ended December 31, 2022, 2021, and 2020 on equity securities sold during the respective periods were not material. As of December 31, 2022, we had approximately $957 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2022, 2021, and 2020. The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2022: Maturities by Period Total Less Than 1-5 6-10 More Than 10 Years Fair value of debt securities $ 646.3 $ 86.2 $ 242.0 $ 104.0 $ 214.1 A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows: 2022 2021 Unrealized gross gains $ 0.6 $ 9.7 Unrealized gross losses 49.2 5.2 Fair value of securities in an unrealized gain position 46.8 250.7 Fair value of securities in an unrealized loss position 568.7 290.2 As of December 31, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 99 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December 31, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities. Activity related to our available-for-sale securities was as follows: 2022 2021 2020 Proceeds from sales $ 132.9 $ 174.7 $ 264.8 Realized gross gains on sales 0.4 2.8 4.5 Realized gross losses on sales 9.7 1.7 8.2 Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Fair Value of Investments The following table summarizes certain fair value information at December 31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Cost (1) Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2022 Cash equivalents (2) $ 657.4 $ 657.4 $ 650.4 $ 7.0 $ — $ 657.4 Short-term investments: U.S. government and agency securities $ 30.8 $ 31.1 $ 30.8 $ — $ — $ 30.8 Corporate debt securities 53.4 53.5 — 53.4 — 53.4 Asset-backed securities 2.0 2.0 — 2.0 — 2.0 Other securities 58.6 58.6 — 39.1 19.5 58.6 Short-term investments $ 144.8 Noncurrent investments: U.S. government and agency securities $ 146.4 $ 163.2 $ 146.4 $ — $ — $ 146.4 Corporate debt securities 213.9 235.8 — 213.9 — 213.9 Mortgage-backed securities 149.2 161.5 — 149.2 — 149.2 Asset-backed securities 50.6 52.5 — 50.6 — 50.6 Other securities 398.6 34.5 — 311.0 87.6 398.6 Marketable equity securities 683.6 484.7 683.6 — — 683.6 Equity investments without readily determinable fair values (3) 478.4 Equity method investments (3) 781.1 Noncurrent investments $ 2,901.8 December 31, 2021 Cash equivalents (2) $ 2,379.5 $ 2,379.5 $ 2,361.0 $ 18.5 $ — $ 2,379.5 Short-term investments: U.S. government and agency securities $ 25.7 $ 25.6 $ 25.7 $ — $ — $ 25.7 Corporate debt securities 43.7 43.7 — 43.7 — 43.7 Mortgage-backed securities 0.2 0.2 — 0.2 — 0.2 Asset-backed securities 6.2 6.2 — 6.2 — 6.2 Other securities 14.3 14.3 — — 14.3 14.3 Short-term investments $ 90.1 Noncurrent investments: U.S. government and agency securities $ 137.0 $ 136.8 $ 137.0 $ — $ — $ 137.0 Corporate debt securities 235.3 232.7 — 235.3 — 235.3 Mortgage-backed securities 109.8 108.1 — 109.8 — 109.8 Asset-backed securities 23.1 23.1 — 23.1 — 23.1 Other securities 108.1 22.2 — — 108.1 108.1 Marketable equity securities 1,279.7 487.0 1,279.7 — — 1,279.7 Equity investments without readily determinable fair values (3) 548.1 Equity method investments (3) 771.5 Noncurrent investments $ 3,212.6 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value. (3) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments. We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. Fair Value of Debt The following table summarizes certain fair value information at December 31, 2022 and 2021 for our short-term and long-term debt: Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair Short-term commercial paper borrowings December 31, 2022 $ (1,498.0) $ — $ (1,492.0) $ — $ (1,492.0) December 31, 2021 — — — — — Long-term debt, including current portion December 31, 2022 $ (14,740.6) $ — $ (12,329.3) $ — $ (12,329.3) December 31, 2021 (16,884.7) — (18,157.7) — (18,157.7) Risk Management and Related Financial Instruments Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings. We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $422.1 million and $550.5 million of accounts receivable as of December 31, 2022 and 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December 31, 2022, 2021, and 2020 were not material. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December 31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days: December 31, 2022 Purchase Sell Currency Amount Currency Amount U.S. dollars 2,516.2 Euro 2,369.2 Euro 3,371.1 U.S. dollars 3,575.3 U.S. dollars 199.8 Chinese yuan 1,396.2 Japanese yen 14,139.9 U.S. dollars 105.3 U.S. dollars 90.9 Japanese yen 12,212.2 British pounds 207.1 U.S. dollars 254.7 Swiss franc 101.4 U.S. dollars 109.3 Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.83 billion and $7.90 billion as of December 31, 2022 and 2021, respectively, of which $5.45 billion and $5.79 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December 31, 2022 and 2021, respectively. At December 31, 2022, we had outstanding cross currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December 31, 2022, we had outstanding foreign currency forward contracts to sell 325.0 million euro and to sell 1.82 billion Chinese yuan, with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December 31, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December 31, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.85 billion, which have settlement dates ranging between 2023 and 2025. The Effect of Risk Management Instruments on the Consolidated Statements of Operations The following effects of risk-management instruments were recognized in other–net, (income) expense: 2022 2021 2020 Fair value hedges: Effect from hedged fixed-rate debt $ (209.8) $ (78.5) $ 86.9 Effect from interest rate contracts 209.8 78.5 (86.9) Cash flow hedges: Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 16.5 16.6 16.4 Cross-currency interest rate swaps 8.6 41.8 (102.4) Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments 191.3 204.6 (123.7) Total $ 216.4 $ 263.0 $ (209.7) During the years ended December 31, 2022, 2021, and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss) The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: 2022 2021 2020 Net investment hedges: Foreign currency-denominated notes $ 324.9 $ 435.0 $ (404.0) Cross-currency interest rate swaps 52.0 213.7 (207.9) Foreign currency forward contracts (15.4) — — Cash flow hedges: Forward-starting interest rate swaps 391.5 97.6 (110.9) Cross-currency interest rate swaps 29.8 42.3 (53.7) During the next 12 months, we expect to reclassify $16.8 million of pretax net losses on cash flow hedges from accumulated other comprehensive income (loss) to other–net, (income) expense. During the years ended December 31, 2022, 2021, and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at December 31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2022 Risk-management instruments Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ (134.3) — $ (134.3) — $ (134.3) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 — 162.9 — 162.9 Other noncurrent assets 246.0 — 246.0 — 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 — 67.6 — 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 — 53.1 — 53.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities (38.3) — (38.3) — (38.3) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 — 26.6 — 26.6 Other current liabilities (21.5) — (21.5) — (21.5) Contingent consideration liabilities: Other current liabilities (39.5) — — (39.5) (39.5) Other noncurrent liabilities (70.6) — — (70.6) (70.6) Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2021 Risk-management instruments Interest rate contracts designated as fair value hedges: Other receivables $ 4.8 $ — $ 4.8 $ — $ 4.8 Other noncurrent assets 78.3 — 78.3 — 78.3 Other noncurrent liabilities (7.6) — (7.6) — (7.6) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 49.2 — 49.2 — 49.2 Other noncurrent liabilities (31.7) — (31.7) — (31.7) Cross-currency interest rate contracts designated as net investment hedges: Other noncurrent assets 31.3 — 31.3 — 31.3 Other current liabilities (1.2) — (1.2) — (1.2) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 33.2 — 33.2 — 33.2 Other noncurrent liabilities (1.3) — (1.3) — (1.3) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.9 — 9.9 — 9.9 Other current liabilities (35.3) — (35.3) — (35.3) Contingent consideration liabilities: Other noncurrent liabilities (70.5) — — (70.5) (70.5) Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Goodwill and Other Intangibles Goodwill Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The change in goodwill during 2022 was primarily related to our acquisition of Akouos. See Note 3 for additional information. No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2022, 2021, and 2020. Other Intangibles The components of intangible assets other than goodwill at December 31 were as follows: 2022 2021 Carrying Accumulated Carrying Carrying Accumulated Carrying Finite-lived intangible assets: Marketed products $ 7,922.1 $ (2,589.9) $ 5,332.2 $ 7,987.2 $ (2,229.2) $ 5,758.0 Other 35.4 (32.8) 2.6 69.4 (60.5) 8.9 Total finite-lived intangible assets 7,957.5 (2,622.7) 5,334.8 8,056.6 (2,289.7) 5,766.9 Indefinite-lived intangible assets: Acquired IPR&D 1,871.8 — 1,871.8 1,925.0 — 1,925.0 Other intangibles $ 9,829.3 $ (2,622.7) $ 7,206.6 $ 9,981.6 $ (2,289.7) $ 7,691.9 Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. Acquired IPR&D consists of the fair values of acquired IPR&D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. The decrease in acquired IPR&D intangibles in 2022 is due to the impairment of an intangible asset for GBA1 Gene Therapy (PR001). See Note 5 for additional information. This decrease was partially offset by acquired IPR&D assets recognized from the acquisition of Akouos. See Note 3 for additional information. Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from one Amortization expense related to finite-lived intangible assets was as follows: 2022 2021 2020 Amortization expense $ 579.7 $ 628.8 $ 428.2 The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2022 is as follows: 2023 2024 2025 2026 2027 Estimated amortization expense $ 497.5 $ 447.7 $ 435.5 $ 424.8 $ 422.9

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three At December 31, property and equipment consisted of the following: 2022 2021 Land $ 256.6 $ 258.7 Buildings 7,915.9 7,588.1 Equipment 9,406.3 8,937.2 Construction in progress 2,798.6 2,177.8 20,377.4 18,961.8 Less accumulated depreciation (10,233.4) (9,976.7) Property and equipment, net $ 10,144.0 $ 8,985.1 Depreciation expense related to property and equipment was as follows: 2022 2021 2020 Depreciation expense $ 816.6 $ 787.0 $ 765.2 Capitalized interest costs were not material for the years ended December 31, 2022, 2021, and 2020. The following table summarizes long-lived assets by geographical area: 2022 2021 Long-lived assets (1) : U.S. and Puerto Rico $ 7,709.7 $ 6,620.0 Ireland 1,898.5 1,702.3 Other foreign countries 1,625.9 1,691.0 Long-lived assets $ 11,234.1 $ 10,013.3 (1) Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Leases We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured. Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December 31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December 31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December 31, 2022, 2021, and 2020. Supplemental balance sheet information related to operating leases as of December 31, 2022 and 2021 was as follows: 2022 2021 Weighted-average remaining lease term 7 years 7 years Weighted-average discount rate 3.6 % 3.0 % Supplemental cash flow information related to operating leases during the years ended December 31, 2022, 2021, and 2020 was as follows: 2022 2021 2020 Operating cash flows from operating leases $ 149.7 $ 156.7 $ 160.9 Right-of-use assets obtained in exchange for new operating lease liabilities 155.4 163.5 136.7 The annual minimum lease payments of our operating lease liabilities as of December 31, 2022 were as follows: 2023 $ 154.2 2024 131.4 2025 115.1 2026 96.1 2027 76.3 After 2027 250.3 Total lease payments 823.4 Less imputed interest 95.2 Total $ 728.2 Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.
Leases	Leases We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured. Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December 31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December 31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December 31, 2022, 2021, and 2020. Supplemental balance sheet information related to operating leases as of December 31, 2022 and 2021 was as follows: 2022 2021 Weighted-average remaining lease term 7 years 7 years Weighted-average discount rate 3.6 % 3.0 % Supplemental cash flow information related to operating leases during the years ended December 31, 2022, 2021, and 2020 was as follows: 2022 2021 2020 Operating cash flows from operating leases $ 149.7 $ 156.7 $ 160.9 Right-of-use assets obtained in exchange for new operating lease liabilities 155.4 163.5 136.7 The annual minimum lease payments of our operating lease liabilities as of December 31, 2022 were as follows: 2023 $ 154.2 2024 131.4 2025 115.1 2026 96.1 2027 76.3 After 2027 250.3 Total lease payments 823.4 Less imputed interest 95.2 Total $ 728.2 Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Borrowings	Borrowings Debt at December 31 consisted of the following: 2022 2021 Short-term commercial paper borrowings $ 1,498.0 $ — Long-term notes 14,815.3 16,741.2 Other long-term debt 6.9 10.8 Unamortized debt issuance costs (77.2) (84.2) Fair value adjustment on hedged long-term notes (4.4) 216.9 Total debt 16,238.6 16,884.7 Less current portion (1,501.1) (1,538.3) Long-term debt $ 14,737.5 $ 15,346.4 The weighted-average effective borrowing rate on short-term commercial paper borrowings at December 31, 2022 was 4.20 percent. The following table summarizes long-term notes at December 31: 2022 2021 2.35% notes due 2022 $ — $ 750.0 3.00% notes due 2022 — 99.2 1.00% euro denominated notes due 2022 — 678.2 0.15% Swiss franc denominated notes due 2024 649.5 654.7 7.125% notes due 2025 217.5 217.5 2.75% notes due 2025 560.6 560.6 1.625% euro denominated notes due 2026 799.3 847.7 5.5% notes due 2027 364.3 364.3 3.1% notes due 2027 401.5 401.5 0.45% Swiss franc denominated notes due 2028 433.0 436.4 3.375% notes due 2029 930.6 930.6 0.42% Japanese yen denominated notes due 2029 172.1 199.0 2.125% euro denominated notes due 2030 799.3 847.7 0.625% euro denominated notes due 2031 639.4 678.2 0.50% euro denominated notes due 2033 639.4 678.2 0.56% Japanese yen denominated notes due 2034 69.7 80.5 6.77% notes due 2036 158.6 158.6 5.55% notes due 2037 444.7 444.7 5.95% notes due 2037 266.8 266.8 3.875% notes due 2039 240.3 240.3 1.625% British pound denominated notes due 2043 301.2 337.1 4.65% notes due 2044 38.3 38.3 3.7% notes due 2045 386.8 386.8 3.95% notes due 2047 347.0 347.0 3.95% notes due 2049 958.2 958.2 1.70% euro denominated notes due 2049 1,065.7 1,130.3 0.97% Japanese yen denominated notes due 2049 57.4 66.3 2.25% notes due 2050 1,250.0 1,250.0 1.125% euro denominated notes due 2051 532.9 565.2 4.15% notes due 2059 591.3 591.3 2.50% notes due 2060 850.0 850.0 1.375% euro denominated notes due 2061 746.0 791.2 Unamortized note discounts (96.1) (105.2) Total long-term notes $ 14,815.3 $ 16,741.2 The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. At December 31, 2022, we had a total of $7.33 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2026 and a $4.00 billion 364-day facility that expires in September 2023, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $4.00 billion facilities as of December 31, 2022. Of the remaining committed bank credit facilities, the outstanding balances as of December 31, 2022 and 2021 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. In September 2021, we issued euro-denominated notes consisting of €600.0 million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives. In September 2021, we issued euro-denominated notes consisting of €500.0 million of 1.125 percent fixed-rate notes due in September 2051 and €700.0 million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of £250.0 million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91 billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50 billion, resulting in a debt extinguishment loss of $405.2 million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $1.50 billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8 million of 3.95 percent notes due 2049, $408.7 million of 4.15 percent notes due 2059, and $219.4 million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. In May 2020, we issued $1.00 billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. The aggregate amounts of maturities on long-term debt for the next five years are as follows: 2023 2024 2025 2026 2027 Maturities on long-term debt $ 3.1 $ 649.5 $ 778.1 $ 799.3 $ 765.8 We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2022 and 2021, including the effects of interest rate swaps for hedged debt obligations, were 2.87 percent and 2.27 percent, respectively. The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows: 2022 2021 2020 Cash payments for interest on borrowings $ 323.7 $ 338.0 $ 345.8 In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares. Stock-based compensation expense and the related tax benefits were as follows: 2022 2021 2020 Stock-based compensation expense $ 371.1 $ 342.8 $ 308.1 Tax benefit 77.9 72.0 64.7 At December 31, 2022, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 50.0 million additional shares. Performance Award Program PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December 31, 2022, 2021, and 2020 were $234.93, $198.57, and $137.33, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.7 million shares, 0.7 million shares, and 1.1 million shares were issued during the years ended December 31, 2022, 2021, and 2020, respectively. Approximately 0.5 million shares are expected to be issued in 2023. As of December 31, 2022, the total remaining unrecognized compensation cost related to nonvested PAs was $38.4 million, which will be amortized over the weighted-average remaining requisite service period of 12 months. Shareholder Value Award Program SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions: 2022 2021 2020 Expected dividend yield 1.60 % 2.50 % 2.50 % Risk-free interest rate 1.57 0.19 1.38 Volatility 32.99 31.42 20.90 Pursuant to this program, approximately 0.5 million shares, 1.0 million shares, and 0.8 million shares were issued during the years ended December 31, 2022, 2021, and 2020, respectively. Approximately 0.3 million shares are expected to be issued in 2023. As of December 31, 2022, the total remaining unrecognized compensation cost related to nonvested SVAs was $43.3 million, which will be amortized over the weighted-average remaining requisite service period of 21 months. Relative Value Award Program RVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the years ended December 31, 2022, 2021 and 2020 were $230.00, $286.71, and $179.90, respectively, determined using the following assumptions: 2022 2021 2020 Expected dividend yield 1.60 % 2.50 % 2.50 % Risk-free interest rate 1.57 0.19 1.38 Volatility 32.86 30.95 19.89 Approximately 0.1 million shares are expected to be issued in 2023. As of December 31, 2022, the total remaining unrecognized compensation cost related to nonvested RVAs was $17.5 million, which will be amortized over the weighted-average remaining requisite service period of 22 months. Restricted Stock Units RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The weighted-average fair values of RSU awards granted during the years ended December 31, 2022, 2021, and 2020 were $239.88, $196.30, and $135.42, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.0 million, 0.7 million, and 1.1 million shares were granted and approximately 0.8 million, 0.6 million, and 0.6 million shares were issued during the years ended December 31, 2022, 2021, and 2020, respectively. Approximately 0.6 million shares are expected to be issued in 2023. As of December 31, 2022, the total remaining unrecognized compensation cost related to nonvested RSUs was $221.6 million, which will be amortized over the weighted-average remaining requisite service period of 25 months.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders' Equity In 2022, 2021, and 2020, we repurchased $1.50 billion, $1.25 billion, and $500.0 million, respectively, of shares associated with our share repurchase programs. As of December 31, 2022, we had $3.25 billion remaining under our $5.00 billion share repurchase program that our board authorized in May 2021. We have 5.0 million authorized shares of preferred stock. As of December 31, 2022 and 2021, no preferred stock was issued. We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2022 and 2021, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2022 and 2021, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2022, 2021, and 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. Following is the composition of income tax expense: 2022 2021 2020 Current: Federal (1) $ 2,153.6 $ 938.5 $ 567.6 Foreign 547.7 466.0 650.4 State 45.5 (28.4) (47.3) Total current tax expense 2,746.8 1,376.1 1,170.7 Deferred: Federal (1,992.4) (977.5) (97.4) Foreign (78.2) 174.6 (16.6) State (114.6) 0.6 (20.5) Total deferred tax benefit (2,185.2) (802.3) (134.5) Income taxes $ 561.6 $ 573.8 $ 1,036.2 (1) The 2022, 2021, and 2020 current tax expense includes $189.5 million, $64.7 million, and $144.4 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards. Significant components of our deferred tax assets and liabilities as of December 31 were as follows: 2022 2021 Deferred tax assets: Purchases of intangible assets $ 2,071.3 $ 2,347.4 Compensation and benefits 427.9 634.7 Tax credit carryforwards 477.6 463.7 Tax loss and other tax carryforwards and carrybacks 626.0 645.4 Sales rebates and discounts 1,312.9 832.3 Correlative tax adjustments 752.5 560.8 Foreign tax redeterminations 267.8 274.9 Operating lease liabilities 147.5 150.0 Capitalized research and development 1,615.4 275.1 Other 361.0 477.9 Total gross deferred tax assets 8,059.9 6,662.2 Valuation allowances (775.1) (875.6) Total deferred tax assets 7,284.8 5,786.6 Deferred tax liabilities: Earnings of foreign subsidiaries (1,226.0) (1,583.3) Intangibles (1,387.9) (1,516.1) Inventories (639.5) (596.4) Prepaid employee benefits (546.5) (560.6) Property and equipment (433.5) (338.7) Financial instruments (215.0) (303.0) Operating lease assets (130.7) (132.6) Total deferred tax liabilities (4,579.1) (5,030.7) Deferred tax assets - net $ 2,705.7 $ 755.9 The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings. At December 31, 2022, based on filed tax returns we have tax credit carryforwards and carrybacks of $873.6 million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $27.1 million, if unused, will expire between 2028 and 2042. The remaining portion of the tax credit carryforwards is related to federal tax credits of $68.6 million, international tax credits of $118.6 million, and state tax credits of $510.5 million, all of which are fully reserved. At December 31, 2022, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $2.52 billion: $319.1 million will expire by 2027; $1.44 billion will expire between 2028 and 2042; and $762.0 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $246.2 million are fully reserved as of December 31, 2022. At December 31, 2022 and 2021, prepaid expenses and other current assets included prepaid taxes of $2.37 billion and $1.98 billion, respectively. Domestic and Puerto Rican companies contributed approximately 33 percent, 28 percent, and 39 percent for the years ended December 31, 2022, 2021, and 2020, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031, which was amended in 2022 to apply the alternate tax regime established by recently enacted Puerto Rico legislation starting in 2023. Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2022 and 2021, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make. Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: 2022 2021 2020 Cash payments of income taxes $ 2,672.9 $ 1,598.8 $ 954.6 In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2022 are as follows: Total Less than 1 Year 1-3 Years 2017 Tax Act Toll Tax $ 1,895.8 $ 475.7 $ 1,420.1 As of December 31, 2022, we have additional noncurrent income tax payables of $2.28 billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: 2022 2021 2020 Income tax at the U.S. federal statutory tax rate $ 1,429.3 $ 1,292.6 $ 1,518.3 Add (deduct): International operations, including Puerto Rico (1) (299.5) (447.5) (297.2) General business credits (155.0) (100.5) (97.9) Foreign-derived intangible income deduction (287.5) (86.7) (71.5) Valuation allowance release (116.4) (19.0) (10.0) Other (9.3) (65.1) (5.5) Income taxes $ 561.6 $ 573.8 $ 1,036.2 (1) Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: 2022 2021 2020 Beginning balance at January 1 $ 2,798.3 $ 2,551.9 $ 2,108.6 Additions based on tax positions related to the current year 274.2 310.3 225.6 Additions for tax positions of prior years 34.6 98.6 310.8 Reductions for tax positions of prior years (10.9) (8.1) (52.4) Settlements (44.8) (38.5) (72.0) Lapses of statutes of limitation (11.8) (49.7) (41.7) Changes related to the impact of foreign currency translation (52.6) (66.2) 73.0 Ending balance at December 31 $ 2,987.0 $ 2,798.3 $ 2,551.9 The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.70 billion at both December 31, 2022 and 2021. We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012. The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made. Interest and penalties related to unrecognized tax benefits are recognized in income tax expense and were not material for the years ended December 31, 2022, 2021, and 2020. Our accrued interest and penalties related to unrecognized tax benefits were $271.5 million and $220.1 million at December 31, 2022 and 2021, respectively.

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Benefits	Retirement Benefits We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: Defined Benefit Retiree Health 2022 2021 2022 2021 Change in benefit obligation: Benefit obligation at beginning of year $ 17,565.0 $ 18,225.5 $ 1,663.8 $ 1,753.7 Service cost 351.7 369.2 46.6 49.2 Interest cost 398.1 337.8 37.8 32.5 Actuarial (gain) loss (4,158.9) (564.3) (395.9) (86.1) Benefits paid (608.9) (630.1) (86.8) (79.3) Foreign currency exchange rate changes and other adjustments (325.0) (173.1) (6.7) (6.2) Benefit obligation at end of year 13,222.0 17,565.0 1,258.8 1,663.8 Change in plan assets: Fair value of plan assets at beginning of year 16,416.0 14,579.0 3,361.4 3,227.0 Actual return on plan assets (2,388.1) 2,458.1 (796.0) 202.6 Employer contribution 118.1 131.2 13.9 11.1 Benefits paid (608.9) (630.1) (86.8) (79.3) Foreign currency exchange rate changes and other adjustments (341.3) (122.2) — — Fair value of plan assets at end of year 13,195.8 16,416.0 2,492.5 3,361.4 Funded status (26.2) (1,149.0) 1,233.7 1,697.6 Unrecognized net actuarial (gain) loss 2,687.2 3,908.2 54.5 (497.2) Unrecognized prior service (benefit) cost 8.4 11.2 (62.2) (117.6) Net amount recognized $ 2,669.4 $ 2,770.4 $ 1,226.0 $ 1,082.8 Amounts recognized in the consolidated balance sheet consisted of: Other noncurrent assets $ 1,208.0 $ 668.5 $ 1,383.4 $ 1,910.2 Other current liabilities (70.4) (68.3) (8.4) (7.9) Accrued retirement benefits (1,163.8) (1,749.3) (141.3) (204.8) Accumulated other comprehensive (income) loss before income taxes 2,695.6 3,919.5 (7.7) (614.7) Net amount recognized $ 2,669.4 $ 2,770.4 $ 1,226.0 $ 1,082.8 The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December 31, 2022 and 2021. The $4.75 billion and $750.4 million declines in benefit obligation in 2022 and 2021, respectively, were both driven primarily by increases in the discount rates. The following represents our weighted-average assumptions as of December 31: Defined Benefit Retiree Health (Percents) 2022 2021 2020 2022 2021 2020 Discount rate for benefit obligation 5.1 % 2.8 % 2.4 % 5.2 % 3.0 % 2.6 % Discount rate for net benefit costs 2.8 2.4 3.0 3.0 2.6 3.3 Rate of compensation increase for benefit obligation 4.3 3.5 3.3 Rate of compensation increase for net benefit costs 3.5 3.3 3.3 Expected return on plan assets for net benefit costs 8.1 6.8 7.3 7.3 5.0 6.0 We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: 2023 2024 2025 2026 2027 2028-2032 Defined benefit pension plans $ 648.2 $ 664.5 $ 682.6 $ 705.9 $ 732.7 $ 4,079.4 Retiree health benefit plans 89.0 91.6 92.4 92.8 93.4 468.3 Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31: 2022 2021 Projected benefit obligation $ 2,211.2 $ 3,360.3 Fair value of plan assets 977.1 1,542.8 Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31: Defined Benefit Retiree Health 2022 2021 2022 2021 Accumulated benefit obligation $ 1,721.7 $ 2,532.0 $ 149.8 $ 212.6 Fair value of plan assets 652.7 973.4 — — The total accumulated benefit obligation for our defined benefit pension plans was $12.01 billion and $16.44 billion at December 31, 2022 and 2021, respectively. Net pension and retiree health benefit expense included the following components: Defined Benefit Retiree Health 2022 2021 2020 2022 2021 2020 Components of net periodic (benefit) cost: Service cost $ 351.7 $ 369.2 $ 325.5 $ 46.6 $ 49.2 $ 40.8 Interest cost 398.1 337.8 425.8 37.8 32.5 43.7 Expected return on plan assets (947.6) (949.3) (901.5) (152.1) (146.2) (158.1) Amortization of prior service (benefit) cost 2.4 4.2 4.5 (54.8) (59.6) (59.5) Recognized actuarial (gain) loss 342.4 487.7 396.3 0.9 3.2 (3.0) Net periodic (benefit) cost $ 147.0 $ 249.6 $ 250.6 $ (121.6) $ (120.9) $ (136.1) The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2022 , 2021, and 2020: Defined Benefit Retiree Health 2022 2021 2020 2022 2021 2020 Actuarial gain (loss) arising during period $ 823.6 $ 2,072.4 $ (663.0) $ (552.2) $ 142.5 $ 238.8 Plan amendments during period — — (2.2) — — — Amortization of prior service (benefit) cost included in net income 2.4 4.2 4.5 (54.8) (59.6) (59.5) Amortization of net actuarial (gain) loss included in net income 342.4 487.7 396.3 0.9 3.2 (3.0) Foreign currency exchange rate changes and other 55.5 47.2 (71.5) (0.9) 1.9 2.4 Total other comprehensive income (loss) during period $ 1,223.9 $ 2,611.5 $ (335.9) $ (607.0) $ 88.0 $ 178.7 We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $170.6 million, $167.3 million, and $164.3 million for the years ended December 31, 2022, 2021, and 2020, respectively. We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2022, 2021, and 2020 were not material. Benefit Plan Investments Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 85 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations. We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk. Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below. The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 75 percent growth investments and 25 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term. Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments. Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements. Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV. Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards. Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses. Other assets include cash and cash equivalents and mark-to-market value of derivatives. The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities. Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2022 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Significant Significant Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S. $ 1,132.4 $ 396.6 $ 0.1 $ — $ 735.7 International 1,177.1 369.4 300.9 — 506.8 Fixed income: Developed markets 2,445.5 19.8 2,058.2 0.1 367.4 Developed markets - repurchase agreements (706.6) 6.4 (713.0) — — Emerging markets 273.5 10.6 32.0 — 230.9 Private alternative investments: Hedge funds 3,249.0 — — — 3,249.0 Equity-like funds 4,014.1 — — 25.4 3,988.7 Real estate 349.1 234.9 — — 114.2 Other 1,261.7 251.0 (131.8) — 1,142.5 Total $ 13,195.8 $ 1,288.7 $ 1,546.4 $ 25.5 $ 10,335.2 Retiree Health Benefit Plans Public equity securities: U.S. $ 104.2 $ 35.7 $ — $ — $ 68.5 International 72.0 31.9 — — 40.1 Fixed income: Developed markets 63.1 — 63.1 — — Emerging markets 21.0 — — — 21.0 Private alternative investments: Hedge funds 294.9 — — — 294.9 Equity-like funds 332.8 — — 2.4 330.4 Cash value of trust owned insurance contract 1,470.8 — 1,470.8 — — Real estate 21.6 21.6 — — — Other 112.1 24.2 (19.9) — 107.8 Total $ 2,492.5 $ 113.4 $ 1,514.0 $ 2.4 $ 862.7 (1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2022. The activity in the Level 3 investments during the year ended December 31, 2022 was not material. The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2021 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Identical Assets Significant Observable Inputs Significant Unobservable Inputs Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S. $ 1,325.4 $ 430.4 $ 0.1 $ 1.2 $ 893.7 International 2,722.7 815.0 — — 1,907.7 Fixed income: Developed markets 4,496.0 2.6 3,356.6 — 1,136.8 Developed markets - repurchase agreements (1,376.2) — (1,376.2) — — Emerging markets 611.0 11.3 250.5 0.1 349.1 Private alternative investments: Hedge funds 3,046.8 — — — 3,046.8 Equity-like funds 3,816.4 2.1 — 5.5 3,808.8 Real estate 630.3 363.8 7.5 10.7 248.3 Other 1,143.6 103.2 263.2 (2.1) 779.3 Total $ 16,416.0 $ 1,728.4 $ 2,501.7 $ 15.4 $ 12,170.5 Retiree Health Benefit Plans Public equity securities: U.S. $ 124.7 $ 40.9 $ — $ 0.1 $ 83.7 International 180.6 47.7 — — 132.9 Fixed income: Developed markets 102.2 — 80.5 — 21.7 Emerging markets 51.6 — 23.7 — 27.9 Private alternative investments: Hedge funds 275.4 — — — 275.4 Equity-like funds 317.8 — — 0.5 317.3 Cash value of trust owned insurance contract 2,166.8 — 2,166.8 — — Real estate 36.2 34.5 0.7 1.0 — Other 106.1 24.4 18.3 (0.1) 63.5 Total $ 3,361.4 $ 147.5 $ 2,290.0 $ 1.5 $ 922.4 (1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2021. The activity in the Level 3 investments during the year ended December 31, 2021 was not material. In 2023, we expect to contribute approximately $30 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2023.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. Patent Litigation Alimta European Patent Litigation In Europe, Alimta (pemetrexed) was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing . Emgality Patent Litigation We are a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA , Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing. Jardiance Patent Litigation In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. Taltz Patent Litigation Beginning in May 2020, Lilly and Novartis Pharma AG (Novartis) had been litigating the validity and alleged infringement by Taltz of certain patents Novartis acquired from Genentech, Inc. (Genentech). As of October 2022, we had pending cases in Ireland, Italy, Switzerland, and the Netherlands where Novartis sought injunctions to stop Taltz commercialization. In October 2022, we entered into a cashless (no-payment) settlement and mutual release agreement with Novartis, which resolved such disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. This matter is closed. Zyprexa Canada Patent Litigation Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing. Product Liability Litigation Byetta® Product Liability We have been named as a defendant in over 500 Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over 800 plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contained allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). All of the MDL and state court lawsuits have been dismissed as of January 2023 and we consider these matters closed. Environmental Proceedings Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup. Other Matters 340B Litigation and Investigations We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing. In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing. We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. Branchburg Manufacturing Facility In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena. Brazil Litigation – Cosmopolis Facility Labor Attorney Litigation First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately one billion Brazilian reais (approximately $184 million as of December 31, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST. In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil’s assets in Brazil, and required Lilly Brasil and Antibióticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil’s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian reais, which ruling was subsequently limited in scope and the security was reduced to 100 million Brazilian reais. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil’s and ABL’s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing. Individual Former Employee Litigation Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process. Puerto Rico Tax Matter In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. Average Manufacturer Price Litigation In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al. , which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing. Health Choice Alliance We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing. Pricing Litigation We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al. (U.S. District Court for the District of New Jersey, 2018); FWK Holdings, LLC v. Novo Nordisk Inc., et al. , a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), and the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023). These lawsuits are at various stages in the litigation process. Investigations, Subpoenas, and Inquiries In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products. We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries. Research Corporation Technologies, Inc. In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) The following table summarizes the activity related to each component of other comprehensive income (loss): (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Beginning balance at January 1, 2020 $ (1,678.0) $ 4.9 $ (4,638.6) $ (211.9) $ (6,523.6) Other comprehensive income (loss) before reclassifications 250.5 6.8 (379.7) (133.8) (256.2) Net amount reclassified from accumulated other comprehensive loss — 3.1 267.3 13.0 283.4 Net other comprehensive income (loss) 250.5 9.9 (112.4) (120.8) 27.2 Balance at December 31, 2020 (1,427.5) 14.8 (4,751.0) (332.7) (6,496.4) Other comprehensive income (loss) before reclassifications (122.7) (11.9) 1,823.4 106.6 1,795.4 Net amount reclassified from accumulated other comprehensive loss — 0.8 344.0 13.1 357.9 Net other comprehensive income (loss) (122.7) (11.1) 2,167.4 119.7 2,153.3 Balance at December 31, 2021 (1,550.2) 3.7 (2,583.6) (213.0) (4,343.1) Other comprehensive income (loss) before reclassifications (324.4) (52.2) 291.5 332.8 247.7 Net amount reclassified from accumulated other comprehensive loss 0.4 11.4 229.8 9.2 250.8 Net other comprehensive income (loss) (324.0) (40.8) 521.3 342.0 498.5 Ending balance at December 31, 2022 $ (1,874.2) $ (37.1) $ (2,062.3) $ 129.0 $ (3,844.6) The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows: Tax benefit (expense) 2022 2021 2020 Foreign currency translation gains/losses $ (75.9) $ (136.2) $ 128.3 Unrealized net gains/losses on securities 12.4 4.7 (4.3) Defined benefit pension and retiree health benefit plans (95.6) (532.0) 44.8 Effective portion of cash flow hedges (90.9) (31.8) 32.1 Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ (250.0) $ (695.3) $ 200.9 Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations. Reclassifications out of accumulated other comprehensive loss were as follows: Details about Accumulated Other Year Ended December 31, Affected Line Item in the Consolidated Statements of Operations 2022 2021 2020 Amortization of retirement benefit items: Prior service benefits, net $ (52.4) $ (55.4) $ (55.0) Other—net, (income) expense Actuarial losses 343.3 490.9 393.3 Other—net, (income) expense Total before tax 290.9 435.5 338.3 Tax benefit (61.1) (91.5) (71.0) Income taxes Net of tax 229.8 344.0 267.3 Other, net of tax 21.0 13.9 16.1 Other—net, (income) expense Total reclassifications for the period, net of tax $ 250.8 $ 357.9 $ 283.4

Other-Net, (Income) Expense

Other-Net, (Income) Expense	12 Months Ended
	Dec. 31, 2022
Nonoperating Income (Expense) [Abstract]
Other-Net, (Income) Expense	Other–Net, (Income) Expense Other–net, (income) expense consisted of the following: 2022 2021 2020 Interest expense $ 331.6 $ 339.8 $ 359.6 Interest income (62.8) (25.4) (33.0) Net investment (gains) losses on equity securities (Note 7) 410.7 (176.9) (1,442.2) Debt extinguishment loss (Note 11) — 405.2 — Retirement benefit plans (372.9) (289.7) (251.8) Other (income) expense 14.3 (51.4) 195.5 Other–net, (income) expense $ 320.9 $ 201.6 $ (1,171.9)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Research and Development Expense and Acquired In-Process Research and Development (IPR&D)	Research and Development Expenses and Acquired In-Process Research and Development (IPR&D) and Development Milestones Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations. Acquired IPR&D and development milestones include the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.
Earnings Per Share (EPS)	Earnings Per Share (EPS)All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.
Foreign Currency Translation	Foreign Currency Translation Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).
Advertising Expenses	Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.
Implementation of New Financial Accounting Standard	Implementation of New Financial Accounting Standards Accounting Standards Update (ASU) 2021-10, Government Assistance , establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. ASU 2020-04, Reference Rate Reform
Business Combinations	Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&D was immediately expensed if the compound has no alternative future use.
Inventories	We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
Investment	Our equity investments are accounted for using three different methods depending on the type of equity investment: • Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. • For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. • Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
Concentration Risk, Credit Risk	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.
Derivatives	Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.
Goodwill and Intangible Assets	Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.
Property, Plant and Equipment	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three
Share-based Compensation, Option and Incentive Plans	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.
Income Taxes	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
Commitments and Contingencies	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table summarizes our revenue recognized in our consolidated statements of operations: 2022 2021 2020 Net product revenue $ 25,462.8 $ 25,957.9 $ 22,694.8 Collaboration and other revenue (1) 3,078.6 2,360.5 1,845.0 Revenue $ 28,541.4 $ 28,318.4 $ 24,539.8 (1) Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively. The following table summarizes revenue by product: U.S. Outside U.S. 2022 2021 2020 2022 2021 2020 Revenue—to unaffiliated customers: Diabetes: Trulicity ® $ 5,688.8 $ 4,914.4 $ 3,835.9 $ 1,750.9 $ 1,557.6 $ 1,232.2 Jardiance (1) 1,194.5 807.3 620.8 871.5 683.5 533.0 Humalog ® (2) 1,191.9 1,320.7 1,485.6 868.7 1,132.3 1,140.3 Humulin ® 730.2 832.9 866.4 289.2 389.6 393.2 Basaglar ® 470.7 588.3 842.3 289.7 304.2 282.1 Mounjaro ® 366.6 — — 115.9 — — Other diabetes 268.4 255.7 258.1 367.8 401.6 344.5 Total diabetes 9,911.1 8,719.3 7,909.1 4,553.7 4,468.8 3,925.3 Oncology: Verzenio ® 1,653.2 834.9 618.2 830.3 515.0 294.4 Cyramza ® 351.4 358.1 381.9 620.0 674.8 650.8 Alimta ® 543.7 1,233.9 1,265.3 384.0 827.5 1,064.7 Erbitux ® 500.1 481.8 480.1 66.4 66.4 56.3 Tyvyt ® — — — 293.3 418.1 308.7 Other oncology 169.7 120.1 46.6 254.1 210.7 152.3 Total oncology 3,218.1 3,028.8 2,792.1 2,448.1 2,712.5 2,527.2 Immunology: Taltz ® 1,724.6 1,542.4 1,288.5 757.4 670.4 500.0 Olumiant ® (3) 148.2 324.1 63.8 682.3 791.0 575.0 Other immunology 20.0 15.3 20.0 12.1 17.6 14.6 Total immunology 1,892.8 1,881.8 1,372.3 1,451.8 1,479.0 1,089.6 Neuroscience: Emgality ® 462.8 434.5 325.9 188.1 142.7 37.0 Zyprexa ® 30.4 39.6 46.1 306.5 390.7 360.5 Cymbalta ® 33.7 38.7 42.1 249.6 542.8 725.6 Other neuroscience 85.5 102.0 73.2 189.6 207.5 220.9 Total neuroscience 612.4 614.8 487.3 933.8 1,283.7 1,344.0 Other: COVID-19 antibodies (4) 2,008.9 1,978.0 850.0 14.7 261.4 21.2 Forteo ® 367.3 441.6 510.3 245.8 360.3 536.0 Cialis ® 35.2 10.6 61.8 552.1 707.9 545.4 Other 144.2 136.1 246.4 151.3 233.9 321.8 Total other 2,555.7 2,566.4 1,668.4 964.0 1,563.5 1,424.4 Revenue $ 18,190.0 $ 16,811.0 $ 14,229.3 $ 10,351.3 $ 11,507.4 $ 10,310.5 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi ® , Synjardy ® , and Trijardy ® XR. (2) Humalog revenue includes insulin lispro. (3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area: 2022 2021 2020 Revenue—to unaffiliated customers (1) : U.S. $ 18,190.0 $ 16,811.0 $ 14,229.3 Europe 4,299.2 4,776.8 4,187.7 Japan 1,747.3 2,367.0 2,583.1 China 1,452.8 1,661.4 1,116.9 Other foreign countries 2,852.0 2,702.2 2,422.7 Revenue $ 28,541.4 $ 28,318.4 $ 24,539.8 Numbers may not add due to rounding.
Schedule of Amounts Recorded for Contract Liabilities	The following table summarizes contract liability balances: 2022 2021 Contract liabilities $ 219.2 $ 262.6

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at December 1, 2022 Cash $ 153.2 Acquired IPR&D (1) 184.0 Goodwill (2) 181.2 Other assets and liabilities, net 28.9 Acquisition date fair value of consideration transferred 547.3 Less: Cash acquired (153.2) Fair value of CVR liability (3) (66.9) Cash paid, net of cash acquired $ 327.2 (1) Acquired IPR&D intangibles primarily relate to GJB2. (2) The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 22, 2021 Cash $ 90.5 Acquired IPR&D (1) 824.0 Goodwill (2) 126.8 Deferred tax liabilities (106.0) Other assets and liabilities, net (31.5) Acquisition date fair value of consideration transferred 903.8 Less: Cash acquired (90.5) Fair value of CVR liability (3) (65.9) Cash paid, net of cash acquired $ 747.4 (1) Acquired IPR&D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information. (2) The goodwill recognized from this acquisition is not deductible for tax purposes.
Schedule of Research and Development Assets Acquired Other than Through Business Combination	The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020. Counterparty Compound(s),Therapy, or Asset Acquisition Month Phase of Development (1) Acquired IPR&D Expense BioMarin Pharmaceutical Inc. Priority Review Voucher February 2022 Not applicable $ 110.0 Foghorn Therapeutics Inc. Pre-clinical targets that could lead to potential new oncology medicines December 2021 Pre-clinical 316.6 Rigel Pharmaceuticals, Inc. R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases March 2021 Phase I 125.0 Precision Biosciences, Inc. Potential in vivo therapies for genetic disorders January 2021 Pre-clinical 107.8 Innovent Biologics, Inc. (Innovent) Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China (2) October 2020 Phase III 200.0 Petra Pharma Corporation (Petra) Mutant-selective PI3K α inhibitor that could lead to potential new medicine May 2020 Pre-clinical 174.8 Disarm Therapeutics, Inc. Disease-modifying therapeutics program for patients with axonal degeneration October 2020 Pre-clinical 126.3 (1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. (2) In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.

Collaborations and Other Arra_2

Collaborations and Other Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Collaborative Arrangements	The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: Net Milestones Capitalized (Deferred) (1) 2022 2021 Jardiance $ 116.2 $ 136.1 Trajenta 63.5 88.5 Basaglar (130.6) (149.3) (1) This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar: 2022 2021 2020 Jardiance $ 2,066.0 $ 1,490.8 $ 1,153.8 Basaglar 760.4 892.5 1,124.4 Trajenta 383.7 372.5 358.5 2022 2021 2020 Olumiant $ 830.5 $ 1,115.1 $ 638.9 2022 2021 2020 Tyvyt $ 293.3 $ 418.1 $ 308.7

Asset Impairment, Restructuri_2

Asset Impairment, Restructuring, and Other Special Charges (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of Other Operating Cost and Expense, by Component	The components of the charges included in asset impairment, restructuring, and other special charges 2022 2021 2020 Asset impairment (gain) and other special charges $ 221.6 $ 303.1 $ (20.0) Severance 23.0 13.0 151.2 Total asset impairment, restructuring, and other special charges $ 244.6 $ 316.1 $ 131.2

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories at December 31 consisted of the following: 2022 2021 Finished products $ 901.2 $ 761.9 Work in process 2,597.7 2,372.7 Raw materials and supplies 801.9 717.2 Total (approximates replacement cost) 4,300.8 3,851.8 Increase to LIFO cost 8.9 34.2 Inventories $ 4,309.7 $ 3,886.0

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value	The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2022: Maturities by Period Total Less Than 1-5 6-10 More Than 10 Years Fair value of debt securities $ 646.3 $ 86.2 $ 242.0 $ 104.0 $ 214.1
Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position	A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows: 2022 2021 Unrealized gross gains $ 0.6 $ 9.7 Unrealized gross losses 49.2 5.2 Fair value of securities in an unrealized gain position 46.8 250.7 Fair value of securities in an unrealized loss position 568.7 290.2
Schedule of Activity Related to Our Available-for-Sale Securities	Activity related to our available-for-sale securities was as follows: 2022 2021 2020 Proceeds from sales $ 132.9 $ 174.7 $ 264.8 Realized gross gains on sales 0.4 2.8 4.5 Realized gross losses on sales 9.7 1.7 8.2
Schedule of Fair Value Information, Assets	The following table summarizes certain fair value information at December 31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Cost (1) Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2022 Cash equivalents (2) $ 657.4 $ 657.4 $ 650.4 $ 7.0 $ — $ 657.4 Short-term investments: U.S. government and agency securities $ 30.8 $ 31.1 $ 30.8 $ — $ — $ 30.8 Corporate debt securities 53.4 53.5 — 53.4 — 53.4 Asset-backed securities 2.0 2.0 — 2.0 — 2.0 Other securities 58.6 58.6 — 39.1 19.5 58.6 Short-term investments $ 144.8 Noncurrent investments: U.S. government and agency securities $ 146.4 $ 163.2 $ 146.4 $ — $ — $ 146.4 Corporate debt securities 213.9 235.8 — 213.9 — 213.9 Mortgage-backed securities 149.2 161.5 — 149.2 — 149.2 Asset-backed securities 50.6 52.5 — 50.6 — 50.6 Other securities 398.6 34.5 — 311.0 87.6 398.6 Marketable equity securities 683.6 484.7 683.6 — — 683.6 Equity investments without readily determinable fair values (3) 478.4 Equity method investments (3) 781.1 Noncurrent investments $ 2,901.8 December 31, 2021 Cash equivalents (2) $ 2,379.5 $ 2,379.5 $ 2,361.0 $ 18.5 $ — $ 2,379.5 Short-term investments: U.S. government and agency securities $ 25.7 $ 25.6 $ 25.7 $ — $ — $ 25.7 Corporate debt securities 43.7 43.7 — 43.7 — 43.7 Mortgage-backed securities 0.2 0.2 — 0.2 — 0.2 Asset-backed securities 6.2 6.2 — 6.2 — 6.2 Other securities 14.3 14.3 — — 14.3 14.3 Short-term investments $ 90.1 Noncurrent investments: U.S. government and agency securities $ 137.0 $ 136.8 $ 137.0 $ — $ — $ 137.0 Corporate debt securities 235.3 232.7 — 235.3 — 235.3 Mortgage-backed securities 109.8 108.1 — 109.8 — 109.8 Asset-backed securities 23.1 23.1 — 23.1 — 23.1 Other securities 108.1 22.2 — — 108.1 108.1 Marketable equity securities 1,279.7 487.0 1,279.7 — — 1,279.7 Equity investments without readily determinable fair values (3) 548.1 Equity method investments (3) 771.5 Noncurrent investments $ 3,212.6 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value. (3) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.
Summary of Fair Value Information, Liabilities	The following table summarizes certain fair value information at December 31, 2022 and 2021 for our short-term and long-term debt: Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair Short-term commercial paper borrowings December 31, 2022 $ (1,498.0) $ — $ (1,492.0) $ — $ (1,492.0) December 31, 2021 — — — — — Long-term debt, including current portion December 31, 2022 $ (14,740.6) $ — $ (12,329.3) $ — $ (12,329.3) December 31, 2021 (16,884.7) — (18,157.7) — (18,157.7)
Schedule of Derivative Instruments	At December 31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days: December 31, 2022 Purchase Sell Currency Amount Currency Amount U.S. dollars 2,516.2 Euro 2,369.2 Euro 3,371.1 U.S. dollars 3,575.3 U.S. dollars 199.8 Chinese yuan 1,396.2 Japanese yen 14,139.9 U.S. dollars 105.3 U.S. dollars 90.9 Japanese yen 12,212.2 British pounds 207.1 U.S. dollars 254.7 Swiss franc 101.4 U.S. dollars 109.3
Schedule of Effects of Risk-Management Instruments Were Recognized in Other–Net, (Income) Expense	The following effects of risk-management instruments were recognized in other–net, (income) expense: 2022 2021 2020 Fair value hedges: Effect from hedged fixed-rate debt $ (209.8) $ (78.5) $ 86.9 Effect from interest rate contracts 209.8 78.5 (86.9) Cash flow hedges: Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 16.5 16.6 16.4 Cross-currency interest rate swaps 8.6 41.8 (102.4) Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments 191.3 204.6 (123.7) Total $ 216.4 $ 263.0 $ (209.7)
Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges	The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: 2022 2021 2020 Net investment hedges: Foreign currency-denominated notes $ 324.9 $ 435.0 $ (404.0) Cross-currency interest rate swaps 52.0 213.7 (207.9) Foreign currency forward contracts (15.4) — — Cash flow hedges: Forward-starting interest rate swaps 391.5 97.6 (110.9) Cross-currency interest rate swaps 29.8 42.3 (53.7)
Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges	The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: 2022 2021 2020 Net investment hedges: Foreign currency-denominated notes $ 324.9 $ 435.0 $ (404.0) Cross-currency interest rate swaps 52.0 213.7 (207.9) Foreign currency forward contracts (15.4) — — Cash flow hedges: Forward-starting interest rate swaps 391.5 97.6 (110.9) Cross-currency interest rate swaps 29.8 42.3 (53.7)
Schedule of Fair Value, by Balance Sheet Grouping	The following table summarizes certain fair value information at December 31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2022 Risk-management instruments Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ (134.3) — $ (134.3) — $ (134.3) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 — 162.9 — 162.9 Other noncurrent assets 246.0 — 246.0 — 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 — 67.6 — 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 — 53.1 — 53.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities (38.3) — (38.3) — (38.3) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 — 26.6 — 26.6 Other current liabilities (21.5) — (21.5) — (21.5) Contingent consideration liabilities: Other current liabilities (39.5) — — (39.5) (39.5) Other noncurrent liabilities (70.6) — — (70.6) (70.6) Fair Value Measurements Using Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair December 31, 2021 Risk-management instruments Interest rate contracts designated as fair value hedges: Other receivables $ 4.8 $ — $ 4.8 $ — $ 4.8 Other noncurrent assets 78.3 — 78.3 — 78.3 Other noncurrent liabilities (7.6) — (7.6) — (7.6) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 49.2 — 49.2 — 49.2 Other noncurrent liabilities (31.7) — (31.7) — (31.7) Cross-currency interest rate contracts designated as net investment hedges: Other noncurrent assets 31.3 — 31.3 — 31.3 Other current liabilities (1.2) — (1.2) — (1.2) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 33.2 — 33.2 — 33.2 Other noncurrent liabilities (1.3) — (1.3) — (1.3) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.9 — 9.9 — 9.9 Other current liabilities (35.3) — (35.3) — (35.3) Contingent consideration liabilities: Other noncurrent liabilities (70.5) — — (70.5) (70.5)

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-lived Intangible Assets other than Goodwill	The components of intangible assets other than goodwill at December 31 were as follows: 2022 2021 Carrying Accumulated Carrying Carrying Accumulated Carrying Finite-lived intangible assets: Marketed products $ 7,922.1 $ (2,589.9) $ 5,332.2 $ 7,987.2 $ (2,229.2) $ 5,758.0 Other 35.4 (32.8) 2.6 69.4 (60.5) 8.9 Total finite-lived intangible assets 7,957.5 (2,622.7) 5,334.8 8,056.6 (2,289.7) 5,766.9 Indefinite-lived intangible assets: Acquired IPR&D 1,871.8 — 1,871.8 1,925.0 — 1,925.0 Other intangibles $ 9,829.3 $ (2,622.7) $ 7,206.6 $ 9,981.6 $ (2,289.7) $ 7,691.9
Schedule of Indefinite-lived Intangible Assets other than Goodwill	The components of intangible assets other than goodwill at December 31 were as follows: 2022 2021 Carrying Accumulated Carrying Carrying Accumulated Carrying Finite-lived intangible assets: Marketed products $ 7,922.1 $ (2,589.9) $ 5,332.2 $ 7,987.2 $ (2,229.2) $ 5,758.0 Other 35.4 (32.8) 2.6 69.4 (60.5) 8.9 Total finite-lived intangible assets 7,957.5 (2,622.7) 5,334.8 8,056.6 (2,289.7) 5,766.9 Indefinite-lived intangible assets: Acquired IPR&D 1,871.8 — 1,871.8 1,925.0 — 1,925.0 Other intangibles $ 9,829.3 $ (2,622.7) $ 7,206.6 $ 9,981.6 $ (2,289.7) $ 7,691.9
Finite-lived Intangible Assets Amortization Expense	Amortization expense related to finite-lived intangible assets was as follows: 2022 2021 2020 Amortization expense $ 579.7 $ 628.8 $ 428.2
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2022 is as follows: 2023 2024 2025 2026 2027 Estimated amortization expense $ 497.5 $ 447.7 $ 435.5 $ 424.8 $ 422.9

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	At December 31, property and equipment consisted of the following: 2022 2021 Land $ 256.6 $ 258.7 Buildings 7,915.9 7,588.1 Equipment 9,406.3 8,937.2 Construction in progress 2,798.6 2,177.8 20,377.4 18,961.8 Less accumulated depreciation (10,233.4) (9,976.7) Property and equipment, net $ 10,144.0 $ 8,985.1 Depreciation expense related to property and equipment was as follows: 2022 2021 2020 Depreciation expense $ 816.6 $ 787.0 $ 765.2
Long-lived Assets by Geographic Areas	The following table summarizes long-lived assets by geographical area: 2022 2021 Long-lived assets (1) : U.S. and Puerto Rico $ 7,709.7 $ 6,620.0 Ireland 1,898.5 1,702.3 Other foreign countries 1,625.9 1,691.0 Long-lived assets $ 11,234.1 $ 10,013.3 (1) Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of Impact of Leases to Consolidated Condensed Financial Statements	Supplemental balance sheet information related to operating leases as of December 31, 2022 and 2021 was as follows: 2022 2021 Weighted-average remaining lease term 7 years 7 years Weighted-average discount rate 3.6 % 3.0 % Supplemental cash flow information related to operating leases during the years ended December 31, 2022, 2021, and 2020 was as follows: 2022 2021 2020 Operating cash flows from operating leases $ 149.7 $ 156.7 $ 160.9 Right-of-use assets obtained in exchange for new operating lease liabilities 155.4 163.5 136.7
Schedule of Maturities of Operating Lease Liabilities	The annual minimum lease payments of our operating lease liabilities as of December 31, 2022 were as follows: 2023 $ 154.2 2024 131.4 2025 115.1 2026 96.1 2027 76.3 After 2027 250.3 Total lease payments 823.4 Less imputed interest 95.2 Total $ 728.2

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Debt at December 31 consisted of the following: 2022 2021 Short-term commercial paper borrowings $ 1,498.0 $ — Long-term notes 14,815.3 16,741.2 Other long-term debt 6.9 10.8 Unamortized debt issuance costs (77.2) (84.2) Fair value adjustment on hedged long-term notes (4.4) 216.9 Total debt 16,238.6 16,884.7 Less current portion (1,501.1) (1,538.3) Long-term debt $ 14,737.5 $ 15,346.4
Summary of Long-term Notes	The following table summarizes long-term notes at December 31: 2022 2021 2.35% notes due 2022 $ — $ 750.0 3.00% notes due 2022 — 99.2 1.00% euro denominated notes due 2022 — 678.2 0.15% Swiss franc denominated notes due 2024 649.5 654.7 7.125% notes due 2025 217.5 217.5 2.75% notes due 2025 560.6 560.6 1.625% euro denominated notes due 2026 799.3 847.7 5.5% notes due 2027 364.3 364.3 3.1% notes due 2027 401.5 401.5 0.45% Swiss franc denominated notes due 2028 433.0 436.4 3.375% notes due 2029 930.6 930.6 0.42% Japanese yen denominated notes due 2029 172.1 199.0 2.125% euro denominated notes due 2030 799.3 847.7 0.625% euro denominated notes due 2031 639.4 678.2 0.50% euro denominated notes due 2033 639.4 678.2 0.56% Japanese yen denominated notes due 2034 69.7 80.5 6.77% notes due 2036 158.6 158.6 5.55% notes due 2037 444.7 444.7 5.95% notes due 2037 266.8 266.8 3.875% notes due 2039 240.3 240.3 1.625% British pound denominated notes due 2043 301.2 337.1 4.65% notes due 2044 38.3 38.3 3.7% notes due 2045 386.8 386.8 3.95% notes due 2047 347.0 347.0 3.95% notes due 2049 958.2 958.2 1.70% euro denominated notes due 2049 1,065.7 1,130.3 0.97% Japanese yen denominated notes due 2049 57.4 66.3 2.25% notes due 2050 1,250.0 1,250.0 1.125% euro denominated notes due 2051 532.9 565.2 4.15% notes due 2059 591.3 591.3 2.50% notes due 2060 850.0 850.0 1.375% euro denominated notes due 2061 746.0 791.2 Unamortized note discounts (96.1) (105.2) Total long-term notes $ 14,815.3 $ 16,741.2
Schedule of Maturities of Long-term Debt	The aggregate amounts of maturities on long-term debt for the next five years are as follows: 2023 2024 2025 2026 2027 Maturities on long-term debt $ 3.1 $ 649.5 $ 778.1 $ 799.3 $ 765.8
Schedule of Additional Borrowings Disclosures	The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows: 2022 2021 2020 Cash payments for interest on borrowings $ 323.7 $ 338.0 $ 345.8

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Additional Stock-Based Compensation Disclosures	Stock-based compensation expense and the related tax benefits were as follows: 2022 2021 2020 Stock-based compensation expense $ 371.1 $ 342.8 $ 308.1 Tax benefit 77.9 72.0 64.7
Share-based Compensation Awards, Fair Value Assumptions Used	The weighted-average fair values of the SVA units granted during the years ended December 31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions: 2022 2021 2020 Expected dividend yield 1.60 % 2.50 % 2.50 % Risk-free interest rate 1.57 0.19 1.38 Volatility 32.99 31.42 20.90 2022 2021 2020 Expected dividend yield 1.60 % 2.50 % 2.50 % Risk-free interest rate 1.57 0.19 1.38 Volatility 32.86 30.95 19.89

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	Following is the composition of income tax expense: 2022 2021 2020 Current: Federal (1) $ 2,153.6 $ 938.5 $ 567.6 Foreign 547.7 466.0 650.4 State 45.5 (28.4) (47.3) Total current tax expense 2,746.8 1,376.1 1,170.7 Deferred: Federal (1,992.4) (977.5) (97.4) Foreign (78.2) 174.6 (16.6) State (114.6) 0.6 (20.5) Total deferred tax benefit (2,185.2) (802.3) (134.5) Income taxes $ 561.6 $ 573.8 $ 1,036.2
Schedule of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets and liabilities as of December 31 were as follows: 2022 2021 Deferred tax assets: Purchases of intangible assets $ 2,071.3 $ 2,347.4 Compensation and benefits 427.9 634.7 Tax credit carryforwards 477.6 463.7 Tax loss and other tax carryforwards and carrybacks 626.0 645.4 Sales rebates and discounts 1,312.9 832.3 Correlative tax adjustments 752.5 560.8 Foreign tax redeterminations 267.8 274.9 Operating lease liabilities 147.5 150.0 Capitalized research and development 1,615.4 275.1 Other 361.0 477.9 Total gross deferred tax assets 8,059.9 6,662.2 Valuation allowances (775.1) (875.6) Total deferred tax assets 7,284.8 5,786.6 Deferred tax liabilities: Earnings of foreign subsidiaries (1,226.0) (1,583.3) Intangibles (1,387.9) (1,516.1) Inventories (639.5) (596.4) Prepaid employee benefits (546.5) (560.6) Property and equipment (433.5) (338.7) Financial instruments (215.0) (303.0) Operating lease assets (130.7) (132.6) Total deferred tax liabilities (4,579.1) (5,030.7) Deferred tax assets - net $ 2,705.7 $ 755.9
Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax	Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: 2022 2021 2020 Cash payments of income taxes $ 2,672.9 $ 1,598.8 $ 954.6 Total Less than 1 Year 1-3 Years 2017 Tax Act Toll Tax $ 1,895.8 $ 475.7 $ 1,420.1
Schedule of Effective Income Tax Rate Reconciliation	Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: 2022 2021 2020 Income tax at the U.S. federal statutory tax rate $ 1,429.3 $ 1,292.6 $ 1,518.3 Add (deduct): International operations, including Puerto Rico (1) (299.5) (447.5) (297.2) General business credits (155.0) (100.5) (97.9) Foreign-derived intangible income deduction (287.5) (86.7) (71.5) Valuation allowance release (116.4) (19.0) (10.0) Other (9.3) (65.1) (5.5) Income taxes $ 561.6 $ 573.8 $ 1,036.2 (1) Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.
Summary of Income Tax Contingencies	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: 2022 2021 2020 Beginning balance at January 1 $ 2,798.3 $ 2,551.9 $ 2,108.6 Additions based on tax positions related to the current year 274.2 310.3 225.6 Additions for tax positions of prior years 34.6 98.6 310.8 Reductions for tax positions of prior years (10.9) (8.1) (52.4) Settlements (44.8) (38.5) (72.0) Lapses of statutes of limitation (11.8) (49.7) (41.7) Changes related to the impact of foreign currency translation (52.6) (66.2) 73.0 Ending balance at December 31 $ 2,987.0 $ 2,798.3 $ 2,551.9

Retirement Benefits (Tables)

Retirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Schedule of Changes in Accumulated Postemployment Benefit Obligations	We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: Defined Benefit Retiree Health 2022 2021 2022 2021 Change in benefit obligation: Benefit obligation at beginning of year $ 17,565.0 $ 18,225.5 $ 1,663.8 $ 1,753.7 Service cost 351.7 369.2 46.6 49.2 Interest cost 398.1 337.8 37.8 32.5 Actuarial (gain) loss (4,158.9) (564.3) (395.9) (86.1) Benefits paid (608.9) (630.1) (86.8) (79.3) Foreign currency exchange rate changes and other adjustments (325.0) (173.1) (6.7) (6.2) Benefit obligation at end of year 13,222.0 17,565.0 1,258.8 1,663.8
Schedule of Changes in Fair Value of Plan Assets	Change in plan assets: Fair value of plan assets at beginning of year 16,416.0 14,579.0 3,361.4 3,227.0 Actual return on plan assets (2,388.1) 2,458.1 (796.0) 202.6 Employer contribution 118.1 131.2 13.9 11.1 Benefits paid (608.9) (630.1) (86.8) (79.3) Foreign currency exchange rate changes and other adjustments (341.3) (122.2) — — Fair value of plan assets at end of year 13,195.8 16,416.0 2,492.5 3,361.4
Schedule of Net Funded Status	Funded status (26.2) (1,149.0) 1,233.7 1,697.6 Unrecognized net actuarial (gain) loss 2,687.2 3,908.2 54.5 (497.2) Unrecognized prior service (benefit) cost 8.4 11.2 (62.2) (117.6) Net amount recognized $ 2,669.4 $ 2,770.4 $ 1,226.0 $ 1,082.8
Schedule of Amounts Recognized in Balance Sheet	Amounts recognized in the consolidated balance sheet consisted of: Other noncurrent assets $ 1,208.0 $ 668.5 $ 1,383.4 $ 1,910.2 Other current liabilities (70.4) (68.3) (8.4) (7.9) Accrued retirement benefits (1,163.8) (1,749.3) (141.3) (204.8) Accumulated other comprehensive (income) loss before income taxes 2,695.6 3,919.5 (7.7) (614.7) Net amount recognized $ 2,669.4 $ 2,770.4 $ 1,226.0 $ 1,082.8
Schedule of Assumptions Used	The following represents our weighted-average assumptions as of December 31: Defined Benefit Retiree Health (Percents) 2022 2021 2020 2022 2021 2020 Discount rate for benefit obligation 5.1 % 2.8 % 2.4 % 5.2 % 3.0 % 2.6 % Discount rate for net benefit costs 2.8 2.4 3.0 3.0 2.6 3.3 Rate of compensation increase for benefit obligation 4.3 3.5 3.3 Rate of compensation increase for net benefit costs 3.5 3.3 3.3 Expected return on plan assets for net benefit costs 8.1 6.8 7.3 7.3 5.0 6.0
Schedule of Expected Benefit Payments	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: 2023 2024 2025 2026 2027 2028-2032 Defined benefit pension plans $ 648.2 $ 664.5 $ 682.6 $ 705.9 $ 732.7 $ 4,079.4 Retiree health benefit plans 89.0 91.6 92.4 92.8 93.4 468.3
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets	Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31: 2022 2021 Projected benefit obligation $ 2,211.2 $ 3,360.3 Fair value of plan assets 977.1 1,542.8
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31: Defined Benefit Retiree Health 2022 2021 2022 2021 Accumulated benefit obligation $ 1,721.7 $ 2,532.0 $ 149.8 $ 212.6 Fair value of plan assets 652.7 973.4 — —
Schedule of Net Benefit Costs	Net pension and retiree health benefit expense included the following components: Defined Benefit Retiree Health 2022 2021 2020 2022 2021 2020 Components of net periodic (benefit) cost: Service cost $ 351.7 $ 369.2 $ 325.5 $ 46.6 $ 49.2 $ 40.8 Interest cost 398.1 337.8 425.8 37.8 32.5 43.7 Expected return on plan assets (947.6) (949.3) (901.5) (152.1) (146.2) (158.1) Amortization of prior service (benefit) cost 2.4 4.2 4.5 (54.8) (59.6) (59.5) Recognized actuarial (gain) loss 342.4 487.7 396.3 0.9 3.2 (3.0) Net periodic (benefit) cost $ 147.0 $ 249.6 $ 250.6 $ (121.6) $ (120.9) $ (136.1)
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2022 , 2021, and 2020: Defined Benefit Retiree Health 2022 2021 2020 2022 2021 2020 Actuarial gain (loss) arising during period $ 823.6 $ 2,072.4 $ (663.0) $ (552.2) $ 142.5 $ 238.8 Plan amendments during period — — (2.2) — — — Amortization of prior service (benefit) cost included in net income 2.4 4.2 4.5 (54.8) (59.6) (59.5) Amortization of net actuarial (gain) loss included in net income 342.4 487.7 396.3 0.9 3.2 (3.0) Foreign currency exchange rate changes and other 55.5 47.2 (71.5) (0.9) 1.9 2.4 Total other comprehensive income (loss) during period $ 1,223.9 $ 2,611.5 $ (335.9) $ (607.0) $ 88.0 $ 178.7
Schedule of Allocation of Plan Assets	The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2022 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Significant Significant Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S. $ 1,132.4 $ 396.6 $ 0.1 $ — $ 735.7 International 1,177.1 369.4 300.9 — 506.8 Fixed income: Developed markets 2,445.5 19.8 2,058.2 0.1 367.4 Developed markets - repurchase agreements (706.6) 6.4 (713.0) — — Emerging markets 273.5 10.6 32.0 — 230.9 Private alternative investments: Hedge funds 3,249.0 — — — 3,249.0 Equity-like funds 4,014.1 — — 25.4 3,988.7 Real estate 349.1 234.9 — — 114.2 Other 1,261.7 251.0 (131.8) — 1,142.5 Total $ 13,195.8 $ 1,288.7 $ 1,546.4 $ 25.5 $ 10,335.2 Retiree Health Benefit Plans Public equity securities: U.S. $ 104.2 $ 35.7 $ — $ — $ 68.5 International 72.0 31.9 — — 40.1 Fixed income: Developed markets 63.1 — 63.1 — — Emerging markets 21.0 — — — 21.0 Private alternative investments: Hedge funds 294.9 — — — 294.9 Equity-like funds 332.8 — — 2.4 330.4 Cash value of trust owned insurance contract 1,470.8 — 1,470.8 — — Real estate 21.6 21.6 — — — Other 112.1 24.2 (19.9) — 107.8 Total $ 2,492.5 $ 113.4 $ 1,514.0 $ 2.4 $ 862.7 (1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2021 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Identical Assets Significant Observable Inputs Significant Unobservable Inputs Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S. $ 1,325.4 $ 430.4 $ 0.1 $ 1.2 $ 893.7 International 2,722.7 815.0 — — 1,907.7 Fixed income: Developed markets 4,496.0 2.6 3,356.6 — 1,136.8 Developed markets - repurchase agreements (1,376.2) — (1,376.2) — — Emerging markets 611.0 11.3 250.5 0.1 349.1 Private alternative investments: Hedge funds 3,046.8 — — — 3,046.8 Equity-like funds 3,816.4 2.1 — 5.5 3,808.8 Real estate 630.3 363.8 7.5 10.7 248.3 Other 1,143.6 103.2 263.2 (2.1) 779.3 Total $ 16,416.0 $ 1,728.4 $ 2,501.7 $ 15.4 $ 12,170.5 Retiree Health Benefit Plans Public equity securities: U.S. $ 124.7 $ 40.9 $ — $ 0.1 $ 83.7 International 180.6 47.7 — — 132.9 Fixed income: Developed markets 102.2 — 80.5 — 21.7 Emerging markets 51.6 — 23.7 — 27.9 Private alternative investments: Hedge funds 275.4 — — — 275.4 Equity-like funds 317.8 — — 0.5 317.3 Cash value of trust owned insurance contract 2,166.8 — 2,166.8 — — Real estate 36.2 34.5 0.7 1.0 — Other 106.1 24.4 18.3 (0.1) 63.5 Total $ 3,361.4 $ 147.5 $ 2,290.0 $ 1.5 $ 922.4 (1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the activity related to each component of other comprehensive income (loss): (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Beginning balance at January 1, 2020 $ (1,678.0) $ 4.9 $ (4,638.6) $ (211.9) $ (6,523.6) Other comprehensive income (loss) before reclassifications 250.5 6.8 (379.7) (133.8) (256.2) Net amount reclassified from accumulated other comprehensive loss — 3.1 267.3 13.0 283.4 Net other comprehensive income (loss) 250.5 9.9 (112.4) (120.8) 27.2 Balance at December 31, 2020 (1,427.5) 14.8 (4,751.0) (332.7) (6,496.4) Other comprehensive income (loss) before reclassifications (122.7) (11.9) 1,823.4 106.6 1,795.4 Net amount reclassified from accumulated other comprehensive loss — 0.8 344.0 13.1 357.9 Net other comprehensive income (loss) (122.7) (11.1) 2,167.4 119.7 2,153.3 Balance at December 31, 2021 (1,550.2) 3.7 (2,583.6) (213.0) (4,343.1) Other comprehensive income (loss) before reclassifications (324.4) (52.2) 291.5 332.8 247.7 Net amount reclassified from accumulated other comprehensive loss 0.4 11.4 229.8 9.2 250.8 Net other comprehensive income (loss) (324.0) (40.8) 521.3 342.0 498.5 Ending balance at December 31, 2022 $ (1,874.2) $ (37.1) $ (2,062.3) $ 129.0 $ (3,844.6) The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows: Tax benefit (expense) 2022 2021 2020 Foreign currency translation gains/losses $ (75.9) $ (136.2) $ 128.3 Unrealized net gains/losses on securities 12.4 4.7 (4.3) Defined benefit pension and retiree health benefit plans (95.6) (532.0) 44.8 Effective portion of cash flow hedges (90.9) (31.8) 32.1 Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ (250.0) $ (695.3) $ 200.9
Schedule of Amounts Recognized in Other Comprehensive Loss	Reclassifications out of accumulated other comprehensive loss were as follows: Details about Accumulated Other Year Ended December 31, Affected Line Item in the Consolidated Statements of Operations 2022 2021 2020 Amortization of retirement benefit items: Prior service benefits, net $ (52.4) $ (55.4) $ (55.0) Other—net, (income) expense Actuarial losses 343.3 490.9 393.3 Other—net, (income) expense Total before tax 290.9 435.5 338.3 Tax benefit (61.1) (91.5) (71.0) Income taxes Net of tax 229.8 344.0 267.3 Other, net of tax 21.0 13.9 16.1 Other—net, (income) expense Total reclassifications for the period, net of tax $ 250.8 $ 357.9 $ 283.4

Other - Net, (Income) Expense (

Other - Net, (Income) Expense (Tables)	12 Months Ended
	Dec. 31, 2022
Nonoperating Income (Expense) [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other–net, (income) expense consisted of the following: 2022 2021 2020 Interest expense $ 331.6 $ 339.8 $ 359.6 Interest income (62.8) (25.4) (33.0) Net investment (gains) losses on equity securities (Note 7) 410.7 (176.9) (1,442.2) Debt extinguishment loss (Note 11) — 405.2 — Retirement benefit plans (372.9) (289.7) (251.8) Other (income) expense 14.3 (51.4) 195.5 Other–net, (income) expense $ 320.9 $ 201.6 $ (1,171.9)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Advertising expense	$ 1	$ 1.2	$ 1.1
Advertising expense, percentage of revenue	5%	5%	5%

Revenue (Summary of Revenue Rec

Revenue (Summary of Revenue Recognized) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 28,541.4	$ 28,318.4	$ 24,539.8
Net product revenue
Disaggregation of Revenue [Line Items]
Revenues	25,462.8	25,957.9	22,694.8
Collaboration and other revenue
Disaggregation of Revenue [Line Items]
Revenues	3,078.6	2,360.5	1,845
Collaboration and other revenue associated with prior period transfers of intellectual property
Disaggregation of Revenue [Line Items]
Revenues	$ 163.4	$ 175	$ 135.6

Revenue (Narrative) (Details)

Revenue (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Change in Accounting Estimate [Line Items]
Revenue, performance obligation, payment terms, days from date of shipment, minimum	30 days
Revenue, performance obligation, payment terms, days from date of shipment, maximum	70 days
Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)	1 year
Revenue, performance obligation, sales rebate payment period (up to)	6 months
Revenue, performance obligation, sales returns, product expiration date	24 months
Revenue, performance obligation, sales returns, average inventory level (or less)	1 month
Revenue, performance obligation, sales returns, percentage of net revenue (less than)	0.02	0.02	0.02
U.S. | Sales returns, rebates, and discounts
Change in Accounting Estimate [Line Items]
Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)	1%	1%	1%
Three Largest Wholesales | Revenue Benchmark | Minimum | Customer Concentration Risk
Change in Accounting Estimate [Line Items]
Concentration risk, percentage	16%	16%	16%
Three Largest Wholesales | Revenue Benchmark | Maximum | Customer Concentration Risk
Change in Accounting Estimate [Line Items]
Concentration risk, percentage	21%	21%	21%
Three Largest Wholesales | Accounts Receivable | Minimum | Customer Concentration Risk
Change in Accounting Estimate [Line Items]
Concentration risk, percentage	18%	18%
Three Largest Wholesales | Accounts Receivable | Maximum | Customer Concentration Risk
Change in Accounting Estimate [Line Items]
Concentration risk, percentage	29%	29%

Revenue (Contract Liabilities)

Revenue (Contract Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract liabilities	$ 219.2	$ 262.6

Revenue (Disaggregation of Reve

Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 28,541.4	$ 28,318.4	$ 24,539.8
U.S.
Disaggregation of Revenue [Line Items]
Revenues	18,190	16,811	14,229.3
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	10,351.3	11,507.4	10,310.5
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenues	9,911.1	8,719.3	7,909.1
Diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	4,553.7	4,468.8	3,925.3
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	5,688.8	4,914.4	3,835.9
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,750.9	1,557.6	1,232.2
Jardiance®
Disaggregation of Revenue [Line Items]
Revenues	2,066	1,490.8	1,153.8
Jardiance® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,194.5	807.3	620.8
Jardiance® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	871.5	683.5	533
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,191.9	1,320.7	1,485.6
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	868.7	1,132.3	1,140.3
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	730.2	832.9	866.4
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	289.2	389.6	393.2
Basaglar®
Disaggregation of Revenue [Line Items]
Revenues	760.4	892.5	1,124.4
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	470.7	588.3	842.3
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	289.7	304.2	282.1
Mounjaro® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	366.6	0	0
Mounjaro® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	115.9	0	0
Other diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenues	268.4	255.7	258.1
Other diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	367.8	401.6	344.5
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenues	3,218.1	3,028.8	2,792.1
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	2,448.1	2,712.5	2,527.2
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,653.2	834.9	618.2
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	830.3	515	294.4
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	351.4	358.1	381.9
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	620	674.8	650.8
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	543.7	1,233.9	1,265.3
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	384	827.5	1,064.7
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	500.1	481.8	480.1
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	66.4	66.4	56.3
Tyvyt®
Disaggregation of Revenue [Line Items]
Revenues	293.3	418.1	308.7
Tyvyt® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	0	0	0
Tyvyt® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	293.3	418.1	308.7
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenues	169.7	120.1	46.6
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	254.1	210.7	152.3
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,892.8	1,881.8	1,372.3
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,451.8	1,479	1,089.6
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,724.6	1,542.4	1,288.5
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	757.4	670.4	500
Olumiant®
Disaggregation of Revenue [Line Items]
Revenues	830.5	1,115.1	638.9
Olumiant® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	148.2	324.1	63.8
Olumiant® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	682.3	791	575
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenues	20	15.3	20
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	12.1	17.6	14.6
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenues	612.4	614.8	487.3
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	933.8	1,283.7	1,344
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	462.8	434.5	325.9
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	188.1	142.7	37
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	30.4	39.6	46.1
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	306.5	390.7	360.5
Cymbalta® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	33.7	38.7	42.1
Cymbalta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	249.6	542.8	725.6
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenues	85.5	102	73.2
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	189.6	207.5	220.9
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenues	2,555.7	2,566.4	1,668.4
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	964	1,563.5	1,424.4
COVID-19 antibodies
Disaggregation of Revenue [Line Items]
Revenues	2,020	2,240	871.2
COVID-19 antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenues	2,008.9	1,978	850
COVID-19 antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	14.7	261.4	21.2
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	367.3	441.6	510.3
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	245.8	360.3	536
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenues	35.2	10.6	61.8
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	552.1	707.9	545.4
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenues	144.2	136.1	246.4
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenues	$ 151.3	$ 233.9	$ 321.8

Revenue (Disaggregation of Re_2

Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 28,541.4	$ 28,318.4	$ 24,539.8
U.S.
Disaggregation of Revenue [Line Items]
Revenues	18,190	16,811	14,229.3
Europe
Disaggregation of Revenue [Line Items]
Revenues	4,299.2	4,776.8	4,187.7
Japan
Disaggregation of Revenue [Line Items]
Revenues	1,747.3	2,367	2,583.1
China
Disaggregation of Revenue [Line Items]
Revenues	1,452.8	1,661.4	1,116.9
Other foreign countries
Disaggregation of Revenue [Line Items]
Revenues	$ 2,852	$ 2,702.2	$ 2,422.7

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ / shares in Units, $ in Millions		1 Months Ended			12 Months Ended
	Jan. 22, 2021 USD ($)	Dec. 31, 2022 USD ($) right $ / shares	Jan. 31, 2021 USD ($) right $ / shares	Feb. 29, 2020 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 01, 2022 USD ($)
Business Acquisition [Line Items]
Acquired in-process research and development and development milestones					$ 908.5	$ 970.1	$ 769.8
Cash paid, net of cash acquired					327.2	747.4	849.3
Goodwill		$ 4,073			4,073	3,892
Repayments of long-term debt					1,560	$ 1,905.4	$ 276.5
Acquired IPR&D Expense					$ 333.8
Akouos Acquisition
Business Acquisition [Line Items]
Business acquisition, share price (in dollars per share) | $ / shares		$ 12.50			$ 12.50
Cash paid, net of cash acquired		$ 327.2
Consideration transferred, number of contingent value rights | right		1
Contingent value right, additional price per share (in dollars per share) | $ / shares		$ 3			$ 3
Contingent value right, additional price per share, aggregate amount		$ 122			$ 122
Goodwill								$ 181.2
Acquired IPR&D								$ 184
Prevail Therapeutics Inc.
Business Acquisition [Line Items]
Business acquisition, share price (in dollars per share) | $ / shares			$ 22.50
Cash paid, net of cash acquired	$ 747.4		$ 747.4
Consideration transferred, number of contingent value rights | right			1
Contingent value right, additional price per share (in dollars per share) | $ / shares			$ 4
Contingent value right, additional price per share, aggregate amount			$ 160
Contingent value right, monthly reduction | $ / shares			$ 0.083
Goodwill	126.8
Acquired IPR&D	824
Deferred tax liabilities	$ 106
Dermira
Business Acquisition [Line Items]
Consideration transferred				$ 849.3
Goodwill				86.8
Acquired IPR&D				1,200
Deferred tax liabilities				49.5
Long-term debt assumed				375.5
Repayments of long-term debt				$ 276.2

Acquisitions (Assets Acquired a

Acquisitions (Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions			1 Months Ended		12 Months Ended
	Dec. 01, 2022	Jan. 22, 2021	Dec. 31, 2022	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 4,073		$ 4,073	$ 3,892
Cash paid, net of cash acquired					$ 327.2	$ 747.4	$ 849.3
Akouos Acquisition
Business Acquisition [Line Items]
Cash	$ 153.2
Acquired IPR&D	184
Goodwill	181.2
Other assets and liabilities, net	28.9
Acquisition date fair value of consideration transferred	547.3
Cash acquired	(153.2)
Fair value of CVR liability	$ (66.9)
Cash paid, net of cash acquired			$ 327.2
Prevail Therapeutics Inc.
Business Acquisition [Line Items]
Cash		$ 90.5
Acquired IPR&D		824
Goodwill		126.8
Deferred tax liabilities		106
Other assets and liabilities, net		(31.5)
Acquisition date fair value of consideration transferred		903.8
Cash acquired		(90.5)
Fair value of CVR liability		(65.9)
Cash paid, net of cash acquired		$ 747.4		$ 747.4

Acquisitions (Asset Acquisition

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions	1 Months Ended						12 Months Ended
	Feb. 28, 2022	Dec. 31, 2021	Mar. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	May 31, 2020	Dec. 31, 2022
Business Acquisition [Line Items]
Acquired IPR&D Expense							$ 333.8
BioMarin Pharmaceutical Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense	$ 110
Foghorn Therapeutics Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense		$ 316.6
Rigel Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense			$ 125
Precision Biosciences, Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense				$ 107.8
Innovent Biologics, Inc. (Innovent)
Business Acquisition [Line Items]
Acquired IPR&D Expense					$ 200
Petra Pharma Corporation (Petra)
Business Acquisition [Line Items]
Acquired IPR&D Expense						$ 174.8
Disarm Therapeutics, Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense					$ 126.3

Collaborations and Other Arra_3

Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details) - Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Jardiance®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	$ 116.2	$ 136.1
Trajenta®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	63.5	88.5
Basaglar®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	$ (130.6)	$ (149.3)

Collaborations and Other Arra_4

Collaborations and Other Arrangements (Net Product Revenue) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 28,541.4	$ 28,318.4	$ 24,539.8
Jardiance®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	2,066	1,490.8	1,153.8
Basaglar®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	760.4	892.5	1,124.4
Trajenta®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	383.7	372.5	358.5
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	830.5	1,115.1	638.9
Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 293.3	$ 418.1	$ 308.7

Collaborations and Other Arra_5

Collaborations and Other Arrangements (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 28,541.4	$ 28,318.4	$ 24,539.8
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 830.5	1,115.1	638.9
Olumiant® | Royalty Payments Received
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations percent (up to)	20%
Olumiant® | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	$ 330	260
Olumiant® | Milestone Payments, Development and Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	100
COVID-19 Antibodies
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	2,020	$ 2,240	$ 871.2
Lebrikizumab | Milestone Payments, Development and Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	65
Lebrikizumab | Milestone Payments, Development and Regulatory | Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	165
Lebrikizumab | Milestone Payments, Sales-based
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	1,250
Lebrikizumab | Milestone Payments, Sales-based | Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	$ 1,030

Asset Impairment, Restructuri_3

Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring and Related Activities [Abstract]
Asset impairment (gain) and other special charges	$ 221.6	$ 303.1	$ (20)
Severance	23	13	151.2
Total asset impairment, restructuring, and other special charges	$ 244.6	$ 316.1	$ 131.2

Asset Impairment, Restructuri_4

Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Restructuring and Related Activities [Abstract]
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset impairment, restructuring, and other special charges (Note 5)
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset impairment, restructuring, and other special charges (Note 5)
Impairment of intangible assets, finite-lived	$ 128
Impairment of intangible assets, indefinite-lived	$ 108.1

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished products	$ 761.9	$ 901.2
Work in process	2,372.7	2,597.7
Raw materials and supplies	717.2	801.9
Total (approximates replacement cost)	3,851.8	4,300.8
Increase to LIFO cost	34.2	8.9
Inventories	3,886	4,309.7
LIFO inventory amount	1,360	$ 1,230
Inventory write-down	$ 339.7

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 CNY (¥)
Derivative [Line Items]
Net investment gains on equity securities	$ (410.7)	$ 176.9	$ 1,442.2
Unfunded commitments to invest in venture capital funds	$ 957
Unfunded commitments to invest in venture capital funds, anticipated payment period	10 years
Percentage of nonperforming assets	99%
Accounts receivable derecognized	$ 422.1	550.5
Average remaining maturity of foreign currency derivatives	12 months
Maximum remaining maturity of foreign currency derivatives	180 days
Long-term debt	$ 14,815.3	16,741.2
Foreign currency-denominated notes, designated as hedge	$ 5,450	5,790
Variable rate	10%			10%	10%
Losses expected to be reclassified in the next 12 months	$ 16.8
Swap U.S Dollars To Euro
Derivative [Line Items]
Derivative liability, notional amount	1,020
Swap Swiss Francs to USD
Derivative [Line Items]
Derivative liability, notional amount	1,000
Sell Euro
Derivative [Line Items]
Derivative asset, notional amount | €				€ 325
Sell Chinese Yuan
Derivative [Line Items]
Derivative asset, notional amount | ¥					¥ 1,820
Forward-starting interest rate swaps | Cash flow hedges | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	1,850
Foreign Currency Denominated Debt
Derivative [Line Items]
Long-term debt	$ 6,830	$ 7,900

Financial Instruments (Schedule

Financial Instruments (Schedule of Contractual Maturities) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Total	$ 646.3
Less Than 1 Year	86.2
1-5 Years	242
6-10 Years	104
More Than 10 Years	$ 214.1

Financial Instruments (Unrealiz

Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Unrealized gross gains	$ 0.6	$ 9.7
Unrealized gross losses	49.2	5.2
Fair value of securities in an unrealized gain position	46.8	250.7
Fair value of securities in an unrealized loss position	$ 568.7	$ 290.2

Financial Instruments (Realized

Financial Instruments (Realized Gains and Losses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Proceeds from sales	$ 132.9	$ 174.7	$ 264.8
Realized gross gains on sales	0.4	2.8	4.5
Realized gross losses on sales	$ 9.7	$ 1.7	$ 8.2

Financial Instruments (Schedu_2

Financial Instruments (Schedule of Fair Value Measurement) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Statement [Line Items]
Noncurrent investments	$ 2,901.8	$ 3,212.6
Carrying Amount
Statement [Line Items]
Cash equivalents	657.4	2,379.5
Short-term investments	144.8	90.1
Equity investments without readily determinable fair values	478.4	548.1
Noncurrent investments	2,901.8	3,212.6
Carrying Amount | U.S. government and agency securities
Statement [Line Items]
Short-term investments	30.8	25.7
Noncurrent investments	146.4	137
Carrying Amount | Corporate debt securities
Statement [Line Items]
Short-term investments	53.4	43.7
Noncurrent investments	213.9	235.3
Carrying Amount | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0.2
Noncurrent investments	149.2	109.8
Carrying Amount | Asset-backed securities
Statement [Line Items]
Short-term investments	2	6.2
Noncurrent investments	50.6	23.1
Carrying Amount | Other securities
Statement [Line Items]
Short-term investments	58.6	14.3
Carrying Amount | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	398.6	108.1
Carrying Amount | Marketable equity securities
Statement [Line Items]
Equity securities	683.6	1,279.7
Carrying Amount | Equity method investments
Statement [Line Items]
Equity method investments	781.1	771.5
Cost
Statement [Line Items]
Cash equivalents	657.4	2,379.5
Cost | U.S. government and agency securities
Statement [Line Items]
Short-term investments	31.1	25.6
Noncurrent investments	163.2	136.8
Cost | Corporate debt securities
Statement [Line Items]
Short-term investments	53.5	43.7
Noncurrent investments	235.8	232.7
Cost | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0.2
Noncurrent investments	161.5	108.1
Cost | Asset-backed securities
Statement [Line Items]
Short-term investments	2	6.2
Noncurrent investments	52.5	23.1
Cost | Other securities
Statement [Line Items]
Short-term investments	58.6	14.3
Cost | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	34.5	22.2
Cost | Marketable equity securities
Statement [Line Items]
Equity securities	484.7	487
Estimate of Fair Value Measurement
Statement [Line Items]
Cash equivalents	657.4	2,379.5
Estimate of Fair Value Measurement | U.S. government and agency securities
Statement [Line Items]
Short-term investments	30.8	25.7
Noncurrent investments	146.4	137
Estimate of Fair Value Measurement | Corporate debt securities
Statement [Line Items]
Short-term investments	53.4	43.7
Noncurrent investments	213.9	235.3
Estimate of Fair Value Measurement | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0.2
Noncurrent investments	149.2	109.8
Estimate of Fair Value Measurement | Asset-backed securities
Statement [Line Items]
Short-term investments	2	6.2
Noncurrent investments	50.6	23.1
Estimate of Fair Value Measurement | Other securities
Statement [Line Items]
Short-term investments	58.6	14.3
Estimate of Fair Value Measurement | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	398.6	108.1
Estimate of Fair Value Measurement | Marketable equity securities
Statement [Line Items]
Equity securities	683.6	1,279.7
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Statement [Line Items]
Cash equivalents	650.4	2,361
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government and agency securities
Statement [Line Items]
Short-term investments	30.8	25.7
Noncurrent investments	146.4	137
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities
Statement [Line Items]
Short-term investments	0	0
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	0	0
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Marketable equity securities
Statement [Line Items]
Equity securities	683.6	1,279.7
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Statement [Line Items]
Cash equivalents	7	18.5
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | U.S. government and agency securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Corporate debt securities
Statement [Line Items]
Short-term investments	53.4	43.7
Noncurrent investments	213.9	235.3
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0.2
Noncurrent investments	149.2	109.8
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Asset-backed securities
Statement [Line Items]
Short-term investments	2	6.2
Noncurrent investments	50.6	23.1
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities
Statement [Line Items]
Short-term investments	39.1	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	311	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Marketable equity securities
Statement [Line Items]
Equity securities	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Statement [Line Items]
Cash equivalents	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | U.S. government and agency securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Corporate debt securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Mortgage-backed securities
Statement [Line Items]
Short-term investments		0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Asset-backed securities
Statement [Line Items]
Short-term investments	0	0
Noncurrent investments	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities
Statement [Line Items]
Short-term investments	19.5	14.3
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities, noncurrent investments
Statement [Line Items]
Equity securities	87.6	108.1
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Marketable equity securities
Statement [Line Items]
Equity securities	$ 0	$ 0

Financial Instruments (Schedu_3

Financial Instruments (Schedule of Short-term and Long-term Classification) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	$ (1,498)	$ 0
Long-term debt, including current portion	(14,815.3)	(16,741.2)
Carrying Amount
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(14,740.6)	(16,884.7)
Carrying Amount | Commercial Paper
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(1,498)	0
Estimate of Fair Value Measurement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(12,329.3)	(18,157.7)
Estimate of Fair Value Measurement | Commercial Paper
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(1,492)	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Estimate of Fair Value Measurement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Estimate of Fair Value Measurement | Commercial Paper
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	0	0
Significant Other Observable Inputs (Level 2) | Estimate of Fair Value Measurement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(12,329.3)	(18,157.7)
Significant Other Observable Inputs (Level 2) | Estimate of Fair Value Measurement | Commercial Paper
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(1,492)	0
Significant Unobservable Inputs (Level 3) | Estimate of Fair Value Measurement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	0	0
Significant Unobservable Inputs (Level 3) | Estimate of Fair Value Measurement | Commercial Paper
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	$ 0	$ 0

Financial Instruments (Schedu_4

Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details) - Dec. 31, 2022 € in Millions, ¥ in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions	USD ($)	EUR (€)	CNY (¥)	JPY (¥)	GBP (£)	CHF (SFr)
Buy USD Sell Euro
Offsetting Assets [Line Items]
Derivative liability, notional amount	$ 2,516.2
Derivative asset, notional amount | €		€ 2,369.2
Buy Euro Sell USD
Offsetting Assets [Line Items]
Derivative liability, notional amount | €		€ 3,371.1
Derivative asset, notional amount	3,575.3
Buy US Dollar Sell Chinese Yuan
Offsetting Assets [Line Items]
Derivative liability, notional amount	199.8
Derivative asset, notional amount | ¥			¥ 1,396.2
Buy Japanese Yen Sell US Dollar
Offsetting Assets [Line Items]
Derivative liability, notional amount | ¥				¥ 14,139.9
Derivative asset, notional amount	105.3
Buy USD Sell Japanese Yen
Offsetting Assets [Line Items]
Derivative liability, notional amount	90.9
Derivative asset, notional amount | ¥				¥ 12,212.2
Buy GBP Sell USD
Offsetting Assets [Line Items]
Derivative liability, notional amount | £					£ 207.1
Derivative asset, notional amount	254.7
Buy Swiss Franc Sell US Dollar
Offsetting Assets [Line Items]
Derivative liability, notional amount | SFr						SFr 101.4
Derivative asset, notional amount	$ 109.3

Financial Instruments (Schedu_5

Financial Instruments (Schedule of Effect of Risk Management) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flow hedges:
Total	$ 216.4	$ 263	$ (209.7)
Hedged Fixed Rate Debt
Cash flow hedges:
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	324.9	435	(404)
Cross-currency interest rate swaps
Cash flow hedges:
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	52	213.7	(207.9)
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	29.8	42.3	(53.7)
Foreign Exchange Contract
Cash flow hedges:
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	(15.4)	0	0
Forward-starting interest rate swaps
Cash flow hedges:
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	391.5	97.6	(110.9)
Designated as Hedging Instrument | Hedged Fixed Rate Debt
Fair value hedges:
Effect from hedged fixed-rate debt	(209.8)	(78.5)	86.9
Designated as Hedging Instrument | Interest Rate Contract
Fair value hedges:
Effect from interest rate contracts	209.8	78.5	(86.9)
Cash flow hedges:
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	16.5	16.6	16.4
Designated as Hedging Instrument | Cross-currency interest rate swaps
Cash flow hedges:
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	8.6	41.8	(102.4)
Not Designated as Hedging Instrument | Foreign Exchange Contract
Cash flow hedges:
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	$ 191.3	$ 204.6	$ (123.7)

Financial Instruments (Schedu_6

Financial Instruments (Schedule of Risk Management Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	$ (39.5)
Other noncurrent liabilities	(70.6)	$ (70.5)
Carrying Amount | Foreign Exchange Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(38.3)
Carrying Amount | Foreign Exchange Contract | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	26.6	9.9
Other current liabilities	(21.5)	(35.3)
Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(39.5)
Other noncurrent liabilities	(70.6)	(70.5)
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(39.5)
Other noncurrent liabilities	(70.6)	(70.5)
Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(38.3)
Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0
Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(38.3)
Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0
Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	26.6	9.9
Other current liabilities	(21.5)	(35.3)
Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Other current liabilities	0	0
Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	26.6	9.9
Other current liabilities	(21.5)	(35.3)
Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Other current liabilities	0	0
Fair value hedges | Carrying Amount | Interest Rate Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities	(134.3)	(7.6)
Other receivables		4.8
Other noncurrent assets		78.3
Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities	(134.3)	(7.6)
Other receivables		4.8
Other noncurrent assets		78.3
Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities	0	0
Other receivables		0
Other noncurrent assets		0
Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities	(134.3)	(7.6)
Other receivables		4.8
Other noncurrent assets		78.3
Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities	0	0
Other receivables		0
Other noncurrent assets		0
Cash flow hedges | Carrying Amount | Interest Rate Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(31.7)
Other receivables	162.9
Other noncurrent assets	246	49.2
Cash flow hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(1.3)
Other noncurrent assets	53.1	33.2
Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(31.7)
Other receivables	162.9
Other noncurrent assets	246	49.2
Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		0
Other receivables	0
Other noncurrent assets	0	0
Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(31.7)
Other receivables	162.9
Other noncurrent assets	246	49.2
Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		0
Other receivables	0
Other noncurrent assets	0	0
Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(1.3)
Other noncurrent assets	53.1	33.2
Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		0
Other noncurrent assets	0	0
Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		(1.3)
Other noncurrent assets	53.1	33.2
Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other noncurrent liabilities		0
Other noncurrent assets	0	0
Net investment hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	67.6
Other noncurrent assets		31.3
Other current liabilities		(1.2)
Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	67.6
Other noncurrent assets		31.3
Other current liabilities		(1.2)
Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0
Other noncurrent assets		0
Other current liabilities		0
Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	67.6
Other noncurrent assets		31.3
Other current liabilities		(1.2)
Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	$ 0
Other noncurrent assets		0
Other current liabilities		$ 0

Goodwill and Other Intangible_2

Goodwill and Other Intangibles (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-lived intangible assets:
Goodwill, impairment loss	$ 0	$ 0	$ 0
Remaining amortization period	13 years
Minimum
Finite-lived intangible assets:
Finite-lived intangible asset, useful life	1 year
Maximum
Finite-lived intangible assets:
Finite-lived intangible asset, useful life	20 years

Goodwill and Other Intangible_3

Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Finite-lived intangible assets:
Carrying Amount, Gross	$ 7,957.5	$ 8,056.6
Accumulated Amortization	(2,622.7)	(2,289.7)
Carrying Amount, Net	5,334.8	5,766.9
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Carrying Amount, Gross	9,829.3	9,981.6
Accumulated Amortization	(2,622.7)	(2,289.7)
Carrying Amount, Net	7,206.6	7,691.9
Acquired IPR&D
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	1,871.8	1,925
Marketed products
Finite-lived intangible assets:
Carrying Amount, Gross	7,922.1	7,987.2
Accumulated Amortization	(2,589.9)	(2,229.2)
Carrying Amount, Net	5,332.2	5,758
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	(2,589.9)	(2,229.2)
Other
Finite-lived intangible assets:
Carrying Amount, Gross	35.4	69.4
Accumulated Amortization	(32.8)	(60.5)
Carrying Amount, Net	2.6	8.9
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ (32.8)	$ (60.5)

Goodwill and Other Intangible_4

Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 579.7	$ 628.8	$ 428.2

Goodwill and Other Intangible_5

Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Estimated amortization expense
2023	$ 497.5
2024	447.7
2025	435.5
2026	424.8
2027	$ 422.9

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022
Building | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	12 years
Building | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	50 years
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	25 years

Property and Equipment (Schedul

Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Land	$ 256.6	$ 258.7
Buildings	7,915.9	7,588.1
Equipment	9,406.3	8,937.2
Construction in progress	2,798.6	2,177.8
Property and equipment, gross	20,377.4	18,961.8
Less accumulated depreciation	(10,233.4)	(9,976.7)
Property and equipment, net	$ 10,144	$ 8,985.1

Property and Equipment (Sched_2

Property and Equipment (Schedule of Depreciation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 816.6	$ 787	$ 765.2

Property and Equipment (Sched_3

Property and Equipment (Schedule of Geographic Information) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Long-lived assets	$ 11,234.1	$ 10,013.3
U.S. and Puerto Rico
Property, Plant and Equipment [Line Items]
Long-lived assets	7,709.7	6,620
Ireland
Property, Plant and Equipment [Line Items]
Long-lived assets	1,898.5	1,702.3
Other foreign countries
Property, Plant and Equipment [Line Items]
Long-lived assets	$ 1,625.9	$ 1,691

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Lessee, lease, remaining lease term (up to)	14 years
Lease expense	$ 148.8	$ 159.4	$ 154.6

Leases (Impact of Leases to Con

Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	7 years	7 years
Weighted-average discount rate	3.60%	3%
Operating cash flows from operating leases	$ 149.7	$ 156.7	$ 160.9
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 155.4	$ 163.5	$ 136.7

Leases (Maturities of Operating

Leases (Maturities of Operating Lease Liabilities) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 154.2
2024	131.4
2025	115.1
2026	96.1
2027	76.3
After 2027	250.3
Total lease payments	823.4
Less imputed interest	95.2
Total	$ 728.2
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other noncurrent liabilities

Borrowings (Schedule of Debt) (

Borrowings (Schedule of Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Short-term commercial paper borrowings	$ 1,498	$ 0
Long-term notes	14,815.3	16,741.2
Other long-term debt	6.9	10.8
Unamortized debt issuance costs	(77.2)	(84.2)
Fair value adjustment on hedged long-term notes	(4.4)	216.9
Total debt	16,238.6	16,884.7
Less current portion	(1,501.1)	(1,538.3)
Long-term debt	$ 14,737.5	$ 15,346.4

Borrowings (Narrative) (Details

Borrowings (Narrative) (Details)	1 Months Ended			12 Months Ended
	Sep. 30, 2021 USD ($)	Aug. 31, 2020 USD ($)	May 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2021 EUR (€)	Sep. 30, 2021 GBP (£)
Debt Instrument [Line Items]
Weighted average interest rate				420%
Line of credit facility, remaining borrowing capacity				$ 7,330,000,000
Debt extinguishment loss (Note 11)				$ 0	$ 405,200,000	$ 0
Description of derivative activity volume percent				10%
Debt instrument, interest rate, effective percentage				2.87%	2.27%
Foreign Currency Denominated Debt
Debt Instrument [Line Items]
Payment for debt extinguishment	$ 1,910,000,000
Extinguishment of debt, amount	1,500,000,000
Debt extinguishment loss (Note 11)	405,200,000
Foreign Currency Denominated Debt | 0.500% Notes due 2033
Debt Instrument [Line Items]
Debt instrument, face amount | €							€ 600,000,000
Stated interest rate							50%	50%
Foreign Currency Denominated Debt | 1.125% Notes due 2051
Debt Instrument [Line Items]
Debt instrument, face amount | €							€ 500,000,000
Stated interest rate							112.50%	112.50%
Foreign Currency Denominated Debt | 1.375% Notes due 2061
Debt Instrument [Line Items]
Debt instrument, face amount | €							€ 700,000,000
Stated interest rate							137.50%	137.50%
Foreign Currency Denominated Debt | 1.625% Notes due 2043
Debt Instrument [Line Items]
Debt instrument, face amount | £								£ 250,000,000
Stated interest rate							162.50%	162.50%
Foreign Currency Denominated Debt | 3.95% notes due 2049
Debt Instrument [Line Items]
Stated interest rate							395%	395%
Extinguishment of debt, amount	541,800,000
Foreign Currency Denominated Debt | 4.15% notes due 2059
Debt Instrument [Line Items]
Stated interest rate							415%	415%
Extinguishment of debt, amount	408,700,000
Foreign Currency Denominated Debt | 3.375% notes due 2029
Debt Instrument [Line Items]
Stated interest rate							337.50%	337.50%
Extinguishment of debt, amount	$ 219,400,000
Senior Notes | 0.500% Notes due 2033
Debt Instrument [Line Items]
Stated interest rate				0.50%
Senior Notes | 1.125% Notes due 2051
Debt Instrument [Line Items]
Stated interest rate				1.125%
Senior Notes | 1.375% Notes due 2061
Debt Instrument [Line Items]
Stated interest rate				1.375%
Senior Notes | 1.625% Notes due 2043
Debt Instrument [Line Items]
Stated interest rate				1.625%
Senior Notes | 3.95% notes due 2049
Debt Instrument [Line Items]
Stated interest rate				3.95%
Senior Notes | 4.15% notes due 2059
Debt Instrument [Line Items]
Stated interest rate				4.15%
Senior Notes | 3.375% notes due 2029
Debt Instrument [Line Items]
Stated interest rate				3.375%
Senior Notes | 2.25% notes due 2050
Debt Instrument [Line Items]
Debt instrument, face amount		$ 250,000,000	$ 1,000,000,000
Stated interest rate		2.25%	2.25%	2.25%
Proceeds from issuance of debt			$ 988,600,000
Senior Notes | 2.50% notes due 2060
Debt Instrument [Line Items]
Debt instrument, face amount		$ 850,000,000
Stated interest rate		2.50%		2.50%
Senior Notes | Senior Notes Due May 2050 and September 2060
Debt Instrument [Line Items]
Proceeds from issuance of debt		$ 1,070,000,000
Maturity Date, 2023
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 3,000,000,000
Maturity Date, 2019
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 4,000,000,000
Debt instrument, term				364 days

Borrowings (Summary of Long-ter

Borrowings (Summary of Long-term Notes) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2020	May 31, 2020
Debt Instrument [Line Items]
Unamortized note discounts	$ (96.1)	$ (105.2)
Total long-term notes	$ 14,815.3	16,741.2
Senior Notes | 2.35% notes due 2022
Debt Instrument [Line Items]
Stated interest rate	2.35%
Long-term notes, gross	$ 0	750
Senior Notes | 3.00% notes due 2022
Debt Instrument [Line Items]
Stated interest rate	3%
Long-term notes, gross	$ 0	99.2
Senior Notes | 1.00% euro denominated notes due 2022
Debt Instrument [Line Items]
Stated interest rate	1%
Long-term notes, gross	$ 0	678.2
Senior Notes | 0.15% Swiss franc denominated notes due 2024
Debt Instrument [Line Items]
Stated interest rate	0.15%
Long-term notes, gross	$ 649.5	654.7
Senior Notes | 7.125% notes due 2025
Debt Instrument [Line Items]
Stated interest rate	7.125%
Long-term notes, gross	$ 217.5	217.5
Senior Notes | 2.75% notes due 2025
Debt Instrument [Line Items]
Stated interest rate	2.75%
Long-term notes, gross	$ 560.6	560.6
Senior Notes | 1.625% euro denominated notes due 2026
Debt Instrument [Line Items]
Stated interest rate	1.625%
Long-term notes, gross	$ 799.3	847.7
Senior Notes | 5.5% notes due 2027
Debt Instrument [Line Items]
Stated interest rate	5.50%
Long-term notes, gross	$ 364.3	364.3
Senior Notes | 3.1% notes due 2027
Debt Instrument [Line Items]
Stated interest rate	3.10%
Long-term notes, gross	$ 401.5	401.5
Senior Notes | 0.45% Swiss franc denominated notes due 2028
Debt Instrument [Line Items]
Stated interest rate	0.45%
Long-term notes, gross	$ 433	436.4
Senior Notes | 3.375% notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.375%
Long-term notes, gross	$ 930.6	930.6
Senior Notes | 0.42% Japanese yen denominated notes due 2029
Debt Instrument [Line Items]
Stated interest rate	0.42%
Long-term notes, gross	$ 172.1	199
Senior Notes | 2.125% euro denominated notes due 2030
Debt Instrument [Line Items]
Stated interest rate	2.125%
Long-term notes, gross	$ 799.3	847.7
Senior Notes | 0.625% euro denominated notes due 2031
Debt Instrument [Line Items]
Stated interest rate	0.625%
Long-term notes, gross	$ 639.4	678.2
Senior Notes | 0.50% euro denominated notes due 2033
Debt Instrument [Line Items]
Stated interest rate	0.50%
Long-term notes, gross	$ 639.4	678.2
Senior Notes | 0.56% Japanese yen denominated notes due 2034
Debt Instrument [Line Items]
Stated interest rate	0.56%
Long-term notes, gross	$ 69.7	80.5
Senior Notes | 6.77% notes due 2036
Debt Instrument [Line Items]
Stated interest rate	6.77%
Long-term notes, gross	$ 158.6	158.6
Senior Notes | 5.55% notes due 2037
Debt Instrument [Line Items]
Stated interest rate	5.55%
Long-term notes, gross	$ 444.7	444.7
Senior Notes | 5.95% notes due 2037
Debt Instrument [Line Items]
Stated interest rate	5.95%
Long-term notes, gross	$ 266.8	266.8
Senior Notes | 3.875% notes due 2039
Debt Instrument [Line Items]
Stated interest rate	3.875%
Long-term notes, gross	$ 240.3	240.3
Senior Notes | 1.625% Notes due 2043
Debt Instrument [Line Items]
Stated interest rate	1.625%
Long-term notes, gross	$ 301.2	337.1
Senior Notes | 4.65% notes due 2044
Debt Instrument [Line Items]
Stated interest rate	4.65%
Long-term notes, gross	$ 38.3	38.3
Senior Notes | 3.7% notes due 2045
Debt Instrument [Line Items]
Stated interest rate	3.70%
Long-term notes, gross	$ 386.8	386.8
Senior Notes | 3.95% notes due 2047
Debt Instrument [Line Items]
Stated interest rate	3.95%
Long-term notes, gross	$ 347	347
Senior Notes | 3.95% notes due 2049
Debt Instrument [Line Items]
Stated interest rate	3.95%
Long-term notes, gross	$ 958.2	958.2
Senior Notes | 1.70% euro denominated notes due 2049
Debt Instrument [Line Items]
Stated interest rate	1.70%
Long-term notes, gross	$ 1,065.7	1,130.3
Senior Notes | 0.97% Japanese yen denominated notes due 2049
Debt Instrument [Line Items]
Stated interest rate	0.97%
Long-term notes, gross	$ 57.4	66.3
Senior Notes | 2.25% notes due 2050
Debt Instrument [Line Items]
Stated interest rate	2.25%		2.25%	2.25%
Long-term notes, gross	$ 1,250	1,250
Senior Notes | 1.125% euro denominated notes due 2051
Debt Instrument [Line Items]
Stated interest rate	1.125%
Long-term notes, gross	$ 532.9	565.2
Senior Notes | 4.15% notes due 2059
Debt Instrument [Line Items]
Stated interest rate	4.15%
Long-term notes, gross	$ 591.3	591.3
Senior Notes | 2.50% notes due 2060
Debt Instrument [Line Items]
Stated interest rate	2.50%		2.50%
Long-term notes, gross	$ 850	850
Senior Notes | 1.375% euro denominated notes due 2061
Debt Instrument [Line Items]
Stated interest rate	1.375%
Long-term notes, gross	$ 746	$ 791.2

Borrowings (Schedule of Debt Ma

Borrowings (Schedule of Debt Maturities) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Maturities on long-term debt
2023	$ 3.1
2024	649.5
2025	778.1
2026	799.3
2027	$ 765.8

Borrowings (Schedule of Cash Pa

Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Cash payments for interest on borrowings	$ 323.7	$ 338	$ 345.8

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 371.1	$ 342.8	$ 308.1
Tax benefit	$ 77.9	$ 72	$ 64.7

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)	50
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	2 years
Weighted average grant date fair value (in dollars per share)	$ 234.93	$ 198.57	$ 137.33
Shares issued in period (in shares)	0.7	0.7	1.1
Shares expected to be issued (in shares)	0.5
Total compensation cost not yet recognized	$ 38.4
Period for recognition of the compensation cost not yet recognized	12 months
Shareholder Value Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Weighted average grant date fair value (in dollars per share)	$ 203.88	$ 230.19	$ 139.14
Shares issued in period (in shares)	0.5	1	0.8
Shares expected to be issued (in shares)	0.3
Total compensation cost not yet recognized	$ 43.3
Period for recognition of the compensation cost not yet recognized	21 months
Relative Value Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Weighted average grant date fair value (in dollars per share)	$ 230	$ 286.71	$ 179.90
Shares expected to be issued (in shares)	0.1
Total compensation cost not yet recognized	$ 17.5
Period for recognition of the compensation cost not yet recognized	22 months
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Weighted average grant date fair value (in dollars per share)	$ 239.88	$ 196.30	$ 135.42
Shares issued in period (in shares)	0.8	0.6	0.6
Shares expected to be issued (in shares)	0.6
Total compensation cost not yet recognized	$ 221.6
Period for recognition of the compensation cost not yet recognized	25 months
Grants in period (in shares)	1	0.7	1.1

Stock-Based Compensation (Sch_2

Stock-Based Compensation (Schedule of Assumptions Used) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shareholder Value Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	1.60%	2.50%	2.50%
Risk-free interest rate	1.57%	0.19%	1.38%
Volatility	32.99%	31.42%	20.90%
Relative Value Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	1.60%	2.50%	2.50%
Risk-free interest rate	1.57%	0.19%	1.38%
Volatility	32.86%	30.95%	19.89%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 31, 2021
Schedule of Equity [Line Items]
Purchase for treasury	$ 1,500	$ 1,250	$ 500
Preferred stock, shares authorized (in shares)	5,000,000
Shares issued (in shares)	0	0
Shares held in employee trust (in shares)	50,000,000	50,000,000
Employee benefit trust	$ 3,013.2	$ 3,013.2
May 2021 Share Repurchase Program
Schedule of Equity [Line Items]
Remaining authorized repurchase amount	$ 3,250
Stock repurchase program, authorized amount				$ 5,000

Income Taxes (Schedule of Compo

Income Taxes (Schedule of Composition of Income Tax Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 2,153.6	$ 938.5	$ 567.6
Foreign	547.7	466	650.4
State	45.5	(28.4)	(47.3)
Total current tax expense	2,746.8	1,376.1	1,170.7
Deferred:
Federal	(1,992.4)	(977.5)	(97.4)
Foreign	(78.2)	174.6	(16.6)
State	(114.6)	0.6	(20.5)
Total deferred tax benefit	(2,185.2)	(802.3)	(134.5)
Income taxes	561.6	573.8	1,036.2
Current federal tax expense, utilization of net operating loss carryforward	$ 189.5	$ 64.7	$ 144.4

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Purchases of intangible assets	$ 2,071.3	$ 2,347.4
Compensation and benefits	427.9	634.7
Tax credit carryforwards	477.6	463.7
Tax loss and other tax carryforwards and carrybacks	626	645.4
Sales rebates and discounts	1,312.9	832.3
Correlative tax adjustments	752.5	560.8
Foreign tax redeterminations	267.8	274.9
Operating lease liabilities	147.5	150
Capitalized research and development	1,615.4	275.1
Other	361	477.9
Total gross deferred tax assets	8,059.9	6,662.2
Valuation allowances	(775.1)	(875.6)
Total deferred tax assets	7,284.8	5,786.6
Deferred tax liabilities:
Earnings of foreign subsidiaries	(1,226)	(1,583.3)
Intangibles	(1,387.9)	(1,516.1)
Inventories	(639.5)	(596.4)
Prepaid employee benefits	(546.5)	(560.6)
Property and equipment	(433.5)	(338.7)
Financial instruments	(215)	(303)
Operating lease assets	(130.7)	(132.6)
Total deferred tax liabilities	(4,579.1)	(5,030.7)
Deferred tax assets, net	$ 2,705.7	$ 755.9

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Prepaid taxes	$ 2,370	$ 1,980
Domestic and Puerto Rican companies contribution	33%	28%	39%
Long-term income taxes payable, estimated timing of future cash outflows not possible	$ 2,280
Unrecognized tax benefits that would impact effective tax rate	1,700	$ 1,700
Accruals for the payment of interest and penalties	271.5	$ 220.1
Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	873.6
Operating loss carryforwards	2,520
Expiration By 2026
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	148.8
Expiration Between 2028 and 2042
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	27.1
Operating loss carryforwards	1,440
Designated Unusable | Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	68.6
Designated Unusable | Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	118.6
Designated Unusable | State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	510.5
Deferred tax assets related to state net operating losses	246.2
Expiration By 2027
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	319.1
No Expiration
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 762

Income Taxes (Schedule of Cash

Income Taxes (Schedule of Cash Payments of Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Cash payments of income taxes	$ 2,672.9	$ 1,598.8	$ 954.6

Income Taxes (Schedule of Futur

Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details) $ in Millions	Dec. 31, 2022 USD ($)
2017 Tax Act Toll Tax
Total	$ 1,895.8
Less than 1 Year	475.7
1-3 Years	$ 1,420.1

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax at the U.S. federal statutory tax rate	$ 1,429.3	$ 1,292.6	$ 1,518.3
Add (deduct):
International operations, including Puerto Rico	(299.5)	(447.5)	(297.2)
General business credits	(155)	(100.5)	(97.9)
Foreign-derived intangible income deduction	(287.5)	(86.7)	(71.5)
Valuation allowance release	(116.4)	(19)	(10)
Other	(9.3)	(65.1)	(5.5)
Income taxes	$ 561.6	$ 573.8	$ 1,036.2

Income Taxes (Schedule of Unrec

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 2,798.3	$ 2,551.9	$ 2,108.6
Additions based on tax positions related to the current year	274.2	310.3	225.6
Additions for tax positions of prior years	34.6	98.6	310.8
Reductions for tax positions of prior years	(10.9)	(8.1)	(52.4)
Settlements	(44.8)	(38.5)	(72)
Lapses of statutes of limitation	(11.8)	(49.7)	(41.7)
Changes related to the impact of foreign currency translation	(52.6)	(66.2)
Changes related to the impact of foreign currency translation			73
Ending balance	$ 2,987	$ 2,798.3	$ 2,551.9

Retirement Benefits (Schedule o

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Pension Plans
Change in benefit obligation:
Benefit obligation at beginning of year	$ 17,565	$ 18,225.5
Service cost	351.7	369.2	$ 325.5
Interest cost	398.1	337.8	425.8
Actuarial (gain) loss	(4,158.9)	(564.3)
Benefits paid	(608.9)	(630.1)
Foreign currency exchange rate changes and other adjustments	(325)	(173.1)
Benefit obligation at end of year	13,222	17,565	18,225.5
Change in plan assets:
Fair value of plan assets at beginning of year	16,416	14,579
Actual return on plan assets	(2,388.1)	2,458.1
Employer contribution	118.1	131.2
Benefits paid	(608.9)	(630.1)
Foreign currency exchange rate changes and other adjustments	(341.3)	(122.2)
Fair value of plan assets at end of year	13,195.8	16,416	14,579
Funded status	(26.2)	(1,149)
Unrecognized net actuarial (gain) loss	2,687.2	3,908.2
Unrecognized prior service (benefit) cost	8.4	11.2
Net amount recognized	2,669.4	2,770.4
Retiree Health Benefit Plans
Change in benefit obligation:
Benefit obligation at beginning of year	1,663.8	1,753.7
Service cost	46.6	49.2	40.8
Interest cost	37.8	32.5	43.7
Actuarial (gain) loss	(395.9)	(86.1)
Benefits paid	(86.8)	(79.3)
Foreign currency exchange rate changes and other adjustments	(6.7)	(6.2)
Benefit obligation at end of year	1,258.8	1,663.8	1,753.7
Change in plan assets:
Fair value of plan assets at beginning of year	3,361.4	3,227
Actual return on plan assets	(796)	202.6
Employer contribution	13.9	11.1
Benefits paid	(86.8)	(79.3)
Foreign currency exchange rate changes and other adjustments	0	0
Fair value of plan assets at end of year	2,492.5	3,361.4	$ 3,227
Funded status	1,233.7	1,697.6
Unrecognized net actuarial (gain) loss	54.5	(497.2)
Unrecognized prior service (benefit) cost	(62.2)	(117.6)
Net amount recognized	$ 1,226	$ 1,082.8

Retirement Benefits (Schedule_2

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Amounts recognized in the consolidated balance sheet consisted of:
Accrued retirement benefits	$ (1,305.1)	$ (1,954.1)
Defined Benefit Pension Plans
Amounts recognized in the consolidated balance sheet consisted of:
Other noncurrent assets	1,208	668.5
Other current liabilities	(70.4)	(68.3)
Accrued retirement benefits	(1,163.8)	(1,749.3)
Accumulated other comprehensive (income) loss before income taxes	2,695.6	3,919.5
Net amount recognized	2,669.4	2,770.4
Retiree Health Benefit Plans
Amounts recognized in the consolidated balance sheet consisted of:
Other noncurrent assets	1,383.4	1,910.2
Other current liabilities	(8.4)	(7.9)
Accrued retirement benefits	(141.3)	(204.8)
Accumulated other comprehensive (income) loss before income taxes	(7.7)	(614.7)
Net amount recognized	$ 1,226	$ 1,082.8

Retirement Benefits (Narrative)

Retirement Benefits (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, period decrease	$ 4,750	$ 750.4
Expense under the plans	$ 170.6	167.3	$ 164.3
Percentage of global investments in plan assets	85%
Defined Benefit Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Total accumulated benefit obligation for our defined benefit pension plans	$ 12,010	$ 16,440
Expected future employer contributions, next fiscal year	$ 30
Marketable equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation	75%
Developed markets
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation	25%

Retirement Benefits (Schedule_3

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Discount rate for benefit obligation	5.10%	2.80%	2.40%
Discount rate for net benefit costs	2.80%	2.40%	3%
Rate of compensation increase for benefit obligation	4.30%	3.50%	3.30%
Rate of compensation increase for net benefit costs	3.50%	3.30%	3.30%
Expected return on plan assets for net benefit costs	8.10%	6.80%	7.30%
Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Discount rate for benefit obligation	5.20%	3%	2.60%
Discount rate for net benefit costs	3%	2.60%	3.30%
Expected return on plan assets for net benefit costs	7.30%	5%	6%

Retirement Benefits (Schedule_4

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Projected benefit obligation	$ 2,211.2	$ 3,360.3
Fair value of plan assets	977.1	1,542.8
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]
Fair value of plan assets	977.1	1,542.8
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]
Total other comprehensive income (loss) during period	616.9	2,699.4	$ (157.1)
Defined Benefit Pension Plans
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2023	648.2
2024	664.5
2025	682.6
2026	705.9
2027	732.7
2028-2032	4,079.4
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Fair value of plan assets	652.7	973.4
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]
Accumulated benefit obligation	1,721.7	2,532
Fair value of plan assets	652.7	973.4
Components of net periodic (benefit) cost:
Service cost	351.7	369.2	325.5
Interest cost	398.1	337.8	425.8
Expected return on plan assets	(947.6)	(949.3)	(901.5)
Amortization of prior service (benefit) cost	2.4	4.2	4.5
Recognized actuarial (gain) loss	342.4	487.7	396.3
Net periodic (benefit) cost	147	249.6	250.6
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]
Actuarial gain (loss) arising during period	823.6	2,072.4	(663)
Plan amendments during period	0	0	(2.2)
Amortization of prior service (benefit) cost included in net income	2.4	4.2	4.5
Amortization of net actuarial (gain) loss included in net income	342.4	487.7	396.3
Foreign currency exchange rate changes and other	55.5	47.2	(71.5)
Total other comprehensive income (loss) during period	1,223.9	2,611.5	(335.9)
Retiree Health Benefit Plans
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2023	89
2024	91.6
2025	92.4
2026	92.8
2027	93.4
2028-2032	468.3
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Fair value of plan assets	0	0
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]
Accumulated benefit obligation	149.8	212.6
Fair value of plan assets	0	0
Components of net periodic (benefit) cost:
Service cost	46.6	49.2	40.8
Interest cost	37.8	32.5	43.7
Expected return on plan assets	(152.1)	(146.2)	(158.1)
Amortization of prior service (benefit) cost	(54.8)	(59.6)	(59.5)
Recognized actuarial (gain) loss	0.9	3.2	(3)
Net periodic (benefit) cost	(121.6)	(120.9)	(136.1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]
Actuarial gain (loss) arising during period	(552.2)	142.5	238.8
Plan amendments during period	0	0	0
Amortization of prior service (benefit) cost included in net income	(54.8)	(59.6)	(59.5)
Amortization of net actuarial (gain) loss included in net income	0.9	3.2	(3)
Foreign currency exchange rate changes and other	(0.9)	1.9	2.4
Total other comprehensive income (loss) during period	$ (607)	$ 88	$ 178.7

Retirement Benefits (Schedule_5

Retirement Benefits (Schedule of Fair Value Disclosures) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	$ 13,195.8	$ 16,416	$ 14,579
Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	2,492.5	3,361.4	$ 3,227
U.S. | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,132.4	1,325.4
U.S. | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	104.2	124.7
International | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,177.1	2,722.7
International | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	72	180.6
Developed markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	2,445.5	4,496
Developed markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	63.1	102.2
Developed markets - repurchase agreements | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	(706.6)	(1,376.2)
Emerging markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	273.5	611
Emerging markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	21	51.6
Hedge funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	3,249	3,046.8
Hedge funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	294.9	275.4
Equity-like funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	4,014.1	3,816.4
Equity-like funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	332.8	317.8
Cash value of trust owned insurance contract | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,470.8	2,166.8
Real estate | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	349.1	630.3
Real estate | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	21.6	36.2
Other | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,261.7	1,143.6
Other | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	112.1	106.1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,288.7	1,728.4
Quoted Prices in Active Markets for Identical Assets (Level 1) | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	113.4	147.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	396.6	430.4
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	35.7	40.9
Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	369.4	815
Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	31.9	47.7
Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	19.8	2.6
Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets - repurchase agreements | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	6.4	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	10.6	11.3
Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	2.1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	234.9	363.8
Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	21.6	34.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	251	103.2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	24.2	24.4
Significant Other Observable Inputs (Level 2) | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,546.4	2,501.7
Significant Other Observable Inputs (Level 2) | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,514	2,290
Significant Other Observable Inputs (Level 2) | U.S. | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0.1	0.1
Significant Other Observable Inputs (Level 2) | U.S. | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | International | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	300.9	0
Significant Other Observable Inputs (Level 2) | International | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Developed markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	2,058.2	3,356.6
Significant Other Observable Inputs (Level 2) | Developed markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	63.1	80.5
Significant Other Observable Inputs (Level 2) | Developed markets - repurchase agreements | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	(713)	(1,376.2)
Significant Other Observable Inputs (Level 2) | Emerging markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	32	250.5
Significant Other Observable Inputs (Level 2) | Emerging markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	23.7
Significant Other Observable Inputs (Level 2) | Hedge funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Hedge funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Equity-like funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Equity-like funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,470.8	2,166.8
Significant Other Observable Inputs (Level 2) | Real estate | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	7.5
Significant Other Observable Inputs (Level 2) | Real estate | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0.7
Significant Other Observable Inputs (Level 2) | Other | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	(131.8)	263.2
Significant Other Observable Inputs (Level 2) | Other | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	(19.9)	18.3
Significant Unobservable Inputs (Level 3) | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	25.5	15.4
Significant Unobservable Inputs (Level 3) | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	2.4	1.5
Significant Unobservable Inputs (Level 3) | U.S. | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	1.2
Significant Unobservable Inputs (Level 3) | U.S. | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0.1
Significant Unobservable Inputs (Level 3) | International | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | International | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Developed markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0.1	0
Significant Unobservable Inputs (Level 3) | Developed markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Developed markets - repurchase agreements | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Emerging markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0.1
Significant Unobservable Inputs (Level 3) | Emerging markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Hedge funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Hedge funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Equity-like funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	25.4	5.5
Significant Unobservable Inputs (Level 3) | Equity-like funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	2.4	0.5
Significant Unobservable Inputs (Level 3) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Real estate | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	10.7
Significant Unobservable Inputs (Level 3) | Real estate | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	1
Significant Unobservable Inputs (Level 3) | Other | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	(2.1)
Significant Unobservable Inputs (Level 3) | Other | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	(0.1)
Investments Valued at Net Asset Value | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	10,335.2	12,170.5
Investments Valued at Net Asset Value | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	862.7	922.4
Investments Valued at Net Asset Value | U.S. | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	735.7	893.7
Investments Valued at Net Asset Value | U.S. | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	68.5	83.7
Investments Valued at Net Asset Value | International | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	506.8	1,907.7
Investments Valued at Net Asset Value | International | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	40.1	132.9
Investments Valued at Net Asset Value | Developed markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	367.4	1,136.8
Investments Valued at Net Asset Value | Developed markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	21.7
Investments Valued at Net Asset Value | Developed markets - repurchase agreements | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Investments Valued at Net Asset Value | Emerging markets | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	230.9	349.1
Investments Valued at Net Asset Value | Emerging markets | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	21	27.9
Investments Valued at Net Asset Value | Hedge funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	3,249	3,046.8
Investments Valued at Net Asset Value | Hedge funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	294.9	275.4
Investments Valued at Net Asset Value | Equity-like funds | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	3,988.7	3,808.8
Investments Valued at Net Asset Value | Equity-like funds | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	330.4	317.3
Investments Valued at Net Asset Value | Cash value of trust owned insurance contract | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Investments Valued at Net Asset Value | Real estate | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	114.2	248.3
Investments Valued at Net Asset Value | Real estate | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	0	0
Investments Valued at Net Asset Value | Other | Defined Benefit Pension Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	1,142.5	779.3
Investments Valued at Net Asset Value | Other | Retiree Health Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]
Fair value of plan assets	$ 107.8	$ 63.5

Contingencies (Details)

Contingencies (Details) R$ in Millions, $ in Millions	1 Months Ended			12 Months Ended		166 Months Ended
	Jun. 30, 2021 BRL (R$) patent	Jul. 31, 2019 BRL (R$)	Jul. 31, 2018 BRL (R$)	Dec. 31, 2022 BRL (R$) site lawsuit patent	Dec. 31, 2022 USD ($) site lawsuit patent	Dec. 31, 2022 lawsuit plaintiff patent site	Oct. 31, 2022 patent
Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Number of sites jointly and severally liable for cleanup (fewer than) | site				10	10	10
Byetta | Product Liability
Loss Contingencies [Line Items]
Number of pending lawsuits				500	500	500
Number of plaintiffs | plaintiff						800
Humalog, Humulin and Forteo
Loss Contingencies [Line Items]
Number of pending lawsuits				2	2	2
Emgality Patent Litigation
Loss Contingencies [Line Items]
Number of patents | patent	2			3	3	3	2
Employee Litigation | Brazil
Loss Contingencies [Line Items]
Damages awarded, value	R$ 100	R$ 500	R$ 300	R$ 1000	$ 184

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 9,154.8
Other comprehensive income (loss) before reclassifications	247.7	$ 1,795.4	$ (256.2)
Net amount reclassified from accumulated other comprehensive loss	250.8	357.9	283.4
Other comprehensive income, net of tax (Note 17)	498.5	2,153.3	27.2
Ending balance	10,775.4	9,154.8
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(4,343.1)	(6,496.4)	(6,523.6)
Ending balance	(3,844.6)	(4,343.1)	(6,496.4)
Foreign Currency Translation Gains (Losses)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,550.2)	(1,427.5)	(1,678)
Other comprehensive income (loss) before reclassifications	(324.4)	(122.7)	250.5
Net amount reclassified from accumulated other comprehensive loss	0.4	0	0
Other comprehensive income, net of tax (Note 17)	(324)	(122.7)	250.5
Ending balance	(1,874.2)	(1,550.2)	(1,427.5)
Unrealized Net Gains (Losses) on Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	3.7	14.8	4.9
Other comprehensive income (loss) before reclassifications	(52.2)	(11.9)	6.8
Net amount reclassified from accumulated other comprehensive loss	11.4	0.8	3.1
Other comprehensive income, net of tax (Note 17)	(40.8)	(11.1)	9.9
Ending balance	(37.1)	3.7	14.8
Defined Benefit Pension and Retiree Health Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(2,583.6)	(4,751)	(4,638.6)
Other comprehensive income (loss) before reclassifications	291.5	1,823.4	(379.7)
Net amount reclassified from accumulated other comprehensive loss	229.8	344	267.3
Other comprehensive income, net of tax (Note 17)	521.3	2,167.4	(112.4)
Ending balance	(2,062.3)	(2,583.6)	(4,751)
Effective Portion of Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(213)	(332.7)	(211.9)
Other comprehensive income (loss) before reclassifications	332.8	106.6	(133.8)
Net amount reclassified from accumulated other comprehensive loss	9.2	13.1	13
Other comprehensive income, net of tax (Note 17)	342	119.7	(120.8)
Ending balance	$ 129	$ (213)	$ (332.7)

Other Comprehensive Income (L_4

Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	$ (250)	$ (695.3)	$ 200.9
Foreign Currency Translation Gains (Losses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	(75.9)	(136.2)	128.3
Unrealized Net Gains (Losses) on Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	12.4	4.7	(4.3)
Defined Benefit Pension and Retiree Health Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	(95.6)	(532)	44.8
Effective Portion of Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	$ (90.9)	$ (31.8)	$ 32.1

Other Comprehensive Income (L_5

Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other, net (income) expense	$ (14.3)	$ 51.4	$ (195.5)
Total before tax	6,806.4	6,155.5	7,229.9
Tax benefit	(561.6)	(573.8)	(1,036.2)
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period, net of tax	250.8	357.9	283.4
Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	290.9	435.5	338.3
Tax benefit	(61.1)	(91.5)	(71)
Total reclassifications for the period, net of tax	229.8	344	267.3
Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other, net (income) expense	(52.4)	(55.4)	(55)
Actuarial losses | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other, net (income) expense	343.3	490.9	393.3
Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other, net (income) expense	$ 21	$ 13.9	$ 16.1

Other - Net, (Income) Expense_2

Other - Net, (Income) Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Nonoperating Income (Expense) [Abstract]
Interest expense	$ 331.6	$ 339.8	$ 359.6
Interest income	(62.8)	(25.4)	(33)
Net investment (gains) losses on equity securities (Note 7)	410.7	(176.9)	(1,442.2)
Debt extinguishment loss (Note 11)	0	405.2	0
Retirement benefit plans	(372.9)	(289.7)	(251.8)
Other (income) expense	14.3	(51.4)	195.5
Other–net, (income) expense	$ 320.9	$ 201.6	$ (1,171.9)